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ABSTRACT 
The primary therapeutic options in minor biliary injury (BDI) after 
cholecystectomy are endoscopic sphincterotomy (ES) only or with stenting 
(EST) depending on the type and severity of injury. 
 Non-steroidal anti-inflammatory drugs (NSAIDs) based mostly on studies 
in high risk patients are recommended agents in prevention post-endoscopic 
retrograde cholangiopancreatography (ERCP) pancreatitis (PEP). The 
diagnosis is traditionally based on plasma or serum amylase analyses. The 
feasibility of an easier and quicker urine trypsinogen-2 (T-2) dipstick method 
in ERCP unit has not been properly explored, hampering its utilisation.  
Acute pancreatitis (AP) initiating of different aetiologies varies in severity, 
from mild AP resolving within days to a severe form (SAP) with organ 
dysfunction (OD) and high morbidity. Most ODs develop after hospital 
admission. Early recognition of these patients would allow the initiation of 
maximal intensive care. 
The aims of this study were (I) to explore whether ES or ES with stenting is 
superior in minor (Amsterdam type A) bile duct leaks, (II) to evaluate if rectal 
diclofenac has a prophylactic effect in PEP in an ERCP unit with low PEP rate, 
(III) to explore the urine T-2 dipstick test in detecting PEP, and (IV) to explore 
whether serum SPINK1, trypsinogens 1 to 3 (T-1, T-3) and a complex of 
trypsin-2 and α? -antitrypsin (trypsin-2-AAT), can predict the development 
of SAP in patients without OD at hospital admission. 
In these four clinical studies, all the patients were referred to Helsinki 
University Hospital (HUH) Abdominal Centre between 2004 and 2018. In 
retrospective study I, 71 ERCP-patients with minor bile leak (Amsterdam type 
A) and native papillae were grouped into ES group (ES group, n=50) and ES 
with stenting group (EST group, n=21). In retrospective study II, 1,000 ERCP 
patients with 100 mg rectal diclofenac formed the diclofenac group (DG), and 
1,000 patients without rectal diclofenac served as a control group (CG). In 
prospective study III, 400 ERCP patients with native papilla and without AP 
were tested with a dipstick test before, and 4 and/or 24 h after ERCP. In 
prospective study IV, 239 patients admitted to the HUH emergency room due 
to AP, SPINK1, T-1, T-2 and T-3, and a trypsin-2-AAT, plasma pancreas 
specific amylase or amylase, creatinine, and C-reactive protein (CRP) were 
measured 0-12 h after admission to hospital. 
Study I revealed no difference in outcomes in the ES and EST groups in the 
closure time of the leak, discharge time from hospital, and in the primary 
healing rate in a high- or low-grade leak. In study II, the incidence of PEP was 
2.8% in both DG and CG groups, and there was no difference between the 
groups in the severity of PEP or in the effect of diclofenac in higher-risk 
subgroups. In study III, a urine T-2 dipstick test in the diagnosis of PEP was 
highly accurate when the test was evaluated with abdominal pain symptoms; 
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the sensitivity, specificity, positive and negative predictive values 4 and 24 h 
after ERCP were 60%, 99%, 71%, 98% and 100%, 98%, 71%, 100%. In study 
IV, serum levels of SPINK1, T-1, T-2, trypsin-2-AAT, and creatinine correlated 
on admission with the severity of AP. SPINK1 was the most accurate predictor 
for development of SAP, followed by T-2. 
In conclusion, ES seems to be equal to ES and stenting in the treatment of 
Amsterdam type A bile duct leaks. In a centre with a low risk of PEP, rectal 
diclofenac showed no preventive effect. In diagnostics of pancreatitis, a 
negative urine T-2 dipstick test rules out PEP 4h after ERCP, while a positive 
test with abdominal pain symptoms accurately reveals PEP. In assessing AP 
patients without OD at the time of hospital admission, SPINK1 appears to be 
a useful predictor of SAP.  
 6 
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ABBREVIATIONS 
AP  acute pancreatitis  
APACHE  acute physiology and chronic health evaluation  
AUC  area under the ROC curve  
BDI  bile duct injury 
CARS  compensatory anti-inflammatory 
response syndrome 
CECT  contrast-enhanced computed tomography  
CRP  C-reactive protein  
CG  control group 
DAMP   damage-associated molecular pattern 
DOR   diagnostic odds ratios  
DG  diclofenac group 
ERCP   endoscopic retrograde cholangiopancreatography 
ERC   endoscopic retrograde cholangiography 
ES  endoscopic sphincterotomy 
EST  endoscopic sphincterotomy and stenting 
ESGE   European Society of Gastrointestinal Endoscopy 
FC-SEMS  fully covered self-expandable metal stent 
HUH  Helsinki University Hospital 
IL  interleukin 
MRI   magnetic resonance imaging  
MMS   modified Marshall score  
NF-κB  nuclear factor κB 
-LR   negative likelihood ratio  
NPV   negative predictive value 
NSAIDS  non-steroidal anti-inflammatory drugs 
OR   odds ratio  
OD  organ dysfunction 
PCT  procalcitonin 
PEP   post-ERCP pancreatitis  
PLA2                                   phospholipase A2 
PPV  positive predictive value  
PSTI  pancreatic secretory trypsin inhibitor 
PTC  percutaneous transhepatic cholangiography 
+LR   positive likelihood ratio  
ROC   receiver-operating characteristic 
RCT  randomised clinical trial 
SAP  severe acute pancreatitis  
SPINK1   serine peptidase inhibitor Kazal-type 1  
SIRS  systemic inflammatory response syndrome 
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Su-PAR soluble urokinase-type plasminogen activator 
receptor 
trypsin-2-AAT  trypsin-2 complexed with α1 -antitrypsin  
T-1   trypsinogen-1 
T-2  trypsinogen-2  
T-3  trypsinogen-3  
TATI  tumour-associated trypsinogen inhibitor  
US  ultra sound 
WON  walled-off necrosis 
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1 INTRODUCTION 
Endoscopic retrograde cholangiopancreatography (ERCP) is a diagnostic and 
therapeutic endoscopic procedure first described in 1968, and over the 
decades it has been developed as a specific tool for pancreatic and biliary 
system disorders. It is efficient in the therapeutics of post cholecystectomy 
biliary duct injury (BDI), which appears as leaks and strictures in the biliary 
tree (Bergman et al., 1996). Treatment options for BDI, depending on type and 
severity of trauma, are endoscopic sphincterotomy (ES) alone in some cases of 
bile leaks, or stenting with or without ES in major leaks and all strictures. The 
most common type of BDI is a leak, and most frequently, in 60-78% of cases, 
the site of the leak is found in the cystic duct remnant (Kaffes et al., 2005, 
Sandha et al., 2004). The European Society of Gastrointestinal Endoscopy 
(ESGE) guideline recommends endoscopic placement of plastic stents in the 
management of minor bile duct leaks (J. M. Dumonceau et al., 2018).  
Post-ERCP pancreatitis (PEP) is the most common and feared 
complication of ERCP, resulting in complex and multifactorial reactions in the 
pancreatic gland due to pancreatic duct opacification, guide wire passages, and 
other instrumentation (Messmann et al., 1997). Despite improvements in 
ERCP techniques and equipment, the incidence of PEP has not significantly 
improved. Studies report incidences of PEP between 2-9% and severe PEP 
between 0.3- 0.6% (Freeman et al., 2004, Andriulli et al., 2007, Ding et al., 
2015). Many pharmacological agents have been investigated in PEP 
prevention, with poor results. Currently, non-steroidal anti-inflammatory 
drugs (NSAIDs) seem the most efficient and studied agent in PEP prevention 
(Yu et al., 2018). ESGE guidelines suggest routine use of rectal NSAIDs for all 
ERCP patients without contraindications (J. Dumonceau et al., 2014). 
Traditionally, PEP diagnosis has been based on measurements of serum or 
plasma amylase or lipase. However, after insult of PEP, trypsinogen-2 (T-2) 
concentrations in urine rapidly increases. A fast dipstick test for urine T-2 has 
been developed and it has been shown to be equal to amylase and lipase 
measurements in diagnosis of acute pancreatitis (AP) and PEP. (Hedstrom et 
al., 1996, M. Kylanpaa-Back et al., 2000, Rompianesi et al., 2017) Only three 
studies have evaluated the use of trypsinogen-2 dipstick test in the diagnosis 
of PEP. The lack of studies may have inhibited the utilisation of the dipstick 
test in ERCP units.  
The course of AP varies, and in the severe form of AP, the development of 
organ dysfunction (OD) can be rapid, leading to multiple organ failure and 
even death. It is crucial to identify those patients prone to developing OD to 
provide optimal treatment in the intensive care unit. Several biomarkers and 
scoring systems have been developed to measure the severity of AP and predict 
the development of OD. None has been sufficiently reliable, and the estimation 
of which of the AP patients need intensive care is based on the clinician’s 
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evaluation. A trustworthy laboratory test that would help in the assessment of 
the development of OD is still lacking. 
In this thesis, we investigated ERCP in the treatment of BDI after 
cholecystectomy and in especially whether ES or ES and stenting is superior 
in minor, Amsterdam type A BDI leaks. Secondly, we focused on PEP, which 
is a rather frequent complication of ERCP. We evaluated the rectal diclofenac 
preventive effects on PEP in a retrospective cohort of 2,000 patients in our low 
PEP rate ERCP unit. We also explored the diagnostics of PEP by examining 
the urine T-2 dipstick test in 400 patients with native papillae. To investigate 
further the diagnostics of AP and especially severe AP, we examined in 238 
patients referred to the emergency room whether serum SPINK1, trypsinogens 
1 to 3, and complex of trypsin-2 and α? -antitrypsin could predict the 
development of OD in patients who presented no signs of OD on arrival at the 
hospital. 
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2 REVIEW OF THE LITERATURE 
 
2.1 ERCP 
Endoscopic retrograde cholangiopancreatography (ERCP) is a diagnostic and 
therapeutic procedure for pancreatic and biliary system disorders. The term 
cholangiopancreatography describes a radiological procedure in which biliary 
and pancreatic ductal systems are cannulated and injected with contrast 
material to gain diagnostic information. Currently, ERCP is mainly used as a 
therapeutic tool, and other less invasive radiological methods should be used 
for diagnostics. McCune described the first ERCP in 1968 (McCune et al., 
1968), and Kawai performed the first therapeutic ERCP in 1974 by cutting the 
muscles of the ampulla Vateri (Kawai et al., 1974). In Finland, Juhani Lehtola 
performed the first ERCP in 1974 at Oulu University Hospital. Since then, 
equipment and techniques have developed enormously.  
 
Table 1.  Indications for ERCP 
Jaundiced patient with biliary obstruction  
Choledochal stones 
Periampullary tumour 
Tumour obstructing biliary tree 
Pancreatitis  
Portal biliopathy 
Biliary trauma after surgery 
Leak 
Stricture 
Sphincter of Oddi dysfunction 
Chronic pancreatitis 
Pain 
Pancreatic fistula 
Persistent pancreatic leak after surgery or trauma 
Infected or symptomatic pseudocyst 
Primary sclerosing cholangitis (PSC) follow-up 
Cholangioscopy  
Pancreatoscopy 
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2.1.1 ERCP INDICATIONS AND THERAPEUTIC TECHNIQUES 
 
ERCP is an invasive procedure with potential and even lethal adverse events. 
The indication of ERCP should always be compared to potential benefits and 
risks. Table 1 shows the indications of ERCP. Therapeutic options are 
endoscopic sphincterotomy (ES) (cutting the muscles of the sphincter of 
Oddi), removal of stones from biliary or pancreatic ducts, stent placement 
across strictures or large non-removable stones or fistulas, balloon dilatation 
of strictures and papilla, ampullectomy of adenomatous neoplasia or 
superficial cancer of the papilla, and intraluminal stone breaking through 
cholangio- or pancreatoscopy.  
2.1.2 ERC IN THERAPEUTICS OF POSTCHOLECYSTECTOMY BILE 
DUCT INJURIES (BDI) 
 BDI after cholecystectomy 
 
Laparoscopic cholecystectomy is one of the most common surgical procedures 
worldwide. Before the laparoscopic era, the incidence of BDI after 
cholecystectomy varied between 0.1 and 0.2% (Gouma, Go, 1994). However, 
after 1990, when laparoscopy became the first choice in the management of 
symptomatic biliary stones, the incidence of BDI has been reported to increase 
by between 0.4 and 1.1%, and it has remained high despite advances in 
technique and technology (Barkun et al., 1997, Nuzzo et al., 2005). However, 
a first sign of a decreasing trend in incidence has been reported in a large-scale 
nationally validated database study in the United States, showing 0.19% 
incidence in post-cholecystectomy BDIs (Mangieri et al., 2018). 
Risk factors leading to BDI can be divided into three groups: 1) patient 
dependent risk factors: obesity, high age, and surgical adhesions; 2) local risk 
factors: aberrant anatomy, inflammation, infection, haemorrhage, and altered 
anatomy due to large biliary stones; 3) operation-related risk factors: surgical 
skills and equipment (Wu et al., 2010).  
BDI can be severe and life-threatening, depending on the site and extension 
of the injury. Bile leaks are the most common type of BDI, and most frequently, 
in 60-78% of cases, the site of the leak is found in the cystic duct stump (Kaffes 
et al., 2005, Sandha et al., 2004), and in 2-26% in the aberrant branch of the 
right hepatic duct (duct of Luschka) (Spanos et al., 2006). The leak can be 
more severe and originate in 9-20% of BDI cases from the common hepatic 
duct, common bile duct, or intrahepatic ducts (Sandha et al., 2004, Kaffes et 
al., 2005, Spanos et al., 2006). Strictures of the bile duct may occur early after 
a surgical procedure as a consequence of a direct trauma such as a thermal 
injury, or partial or total clipping of the duct. It can also develop due to local 
Review of the literature 
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conditions such as inflammation, infection, or bile leak. Bile duct stricture may 
develop, or become obvious, months or even years after surgery. Late stricture 
is considered to develop as a result of periductal inflammation and fibrosis 
after bile leaks or ischemia due to a damaged local arterial supply. Patients 
after T-tube reconstruction of partial or total common bile duct laceration 
have up to a 50 % possibility of developing a stricture (Wudel et al., 2001). 
 Diagnosis and symptoms of BDI 
 
Only 15-25% of BDIs are diagnosed during cholecystectomy (Nordin et al., 
2002, Way et al., 2003, Karvonen et al., 2011). If BDI is suspected during 
cholecystectomy, intraoperative cholangiography should be performed to 
clarify the anatomy and to determine the site of injury. It is sometimes 
necessary to convert the operation to an open cholecystectomy to avoid further 
complications. If a skilled hepatobiliary surgeon is available, primary repair is 
an option. Otherwise, multiple drain placement and a patient referral to a 
hepatobiliary surgeon is recommended (Perera et al., 2011). 
BDI should be suspected in patients with visible bile in drains after surgery, 
bile emerging from surgical wounds, or in patients who fail to recover and 
develop abdominal pain after cholecystectomy. Symptoms are often 
unspecific, including pain, nausea, fever, sepsis, hyperbilirubinemia (from bile 
peritonitis or biloma), and jaundice (especially in cases of occlusion in the 
common bile duct). Diagnostic delay increases complications and morbidity. 
(de Reuver et al., 2007)  
Current options for BDI diagnostics are ultra-sound (US), contrast-
enhanced computed tomography (CECT), magnetic resonance imaging (MRI), 
magnetic resonance cholangiopancreatography (MRCP), percutaneous 
transhepatic cholangiography (PTC), and ERCP. US reveals fluid collections 
and dilated bile ducts. If fluid collection is detected, an US or CT guided 
percutaneous puncture and aspiration of bile, as well as drain insertion, 
should be performed to confirm diagnosis (C. M. Lee et al, 2000). CECT is 
superior to US because it provides more information on intra-abdominal fluid 
collections, abscesses, bile duct dilatations, and arterial traumas 
(Mbarushimana et al., 2014). Conventional MRCP has limitations in the 
evaluation of biliary leaks providing only morphologic information about 
damage. However, the most accurate diagnosis of biliary leaks is obtained with 
gadolinium-ethoxybenzyl-diethylenetriamine penta-acetic acid (Gd-BOPTA, 
Primovist®)-enhanced MRCP, showing the site of the leak in up to 80% of 
cases (Cieszanowski et al., 2013, Ratcliffe et al., 2014). ERCP visualises the 
injury and often offers option of simultaneous treatment. If there is a suspicion 
of total disconnection, PTC is indicated to explore the anatomy of proximal 
biliary tree, e.g. before biliary reconstruction surgery. If an abdominal drain 
produces bile after surgery, it can serve as a route for cholangiography 
(Schipper et al., 1996). Diagnostic laparoscopy or laparotomy is indicated only 
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if biliary peritonitis does not respond to percutaneous drainage (Nordin et al., 
2011).  
 Classification of BDI 
 
Several classifications have been developed to describe postoperative BDIs. 
Bismuth et al. designed the first classification, which categorises only biliary 
strictures (Bismuth, Majno, 2001). Strasberg and colleagues further 
developed Bismuth’s classification to describe not only strictures but also 
leaks, complete trans-sections, and occlusions (Strasberg et al., 1995). The 
Stewart-Way classification with four injury types describes the mechanism 
of the BDI, as well as its anatomy. It differentiates strictures and resectional 
injuries, but it does not include cystic stump leaks (Stewart, 2014). Biliary 
endoscopists often use the Amsterdam classification, which is very 
practical for endoscopic purposes and helps to choose the endoscopic 
treatment. The Amsterdam classification is divided into four classes 
describing minor and major leaks in the biliary tree, strictures, and occlusion 
of the main bile duct (Bergman et al., 1996) (Figure 1). 
      
                         
 
Figure 1 Amsterdam classification A = minor bile duct leaks, B = major bile duct leaks with or 
without strictures, C = strictures, D = complete trans-sections 
Review of the literature 
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 Endoscopic treatment options for BDI  
 
Before the development of ERCP techniques BDIs were treated operatively. 
Since endoscopic treatment has lower morbidity and mortality compared to 
surgery, it has become the first method of choice in BDI treatment (Tocchi et 
al., 2000). In up to 90% of Amsterdam type A, B, and C BDIs after 
cholecystectomy endoscopic treatment is successful (Karvonen et al., 2011). 
There is no clear consensus concerning the preferred treatment option due to 
the scarce prospective research on the subject. Treatment options for leaks are 
ES with or without stenting, and for strictures ES and stenting. Options for 
stenting are single or multiple plastic stents, a fully covered self-expandable 
metal stent (FC-SEMS), bio-degradable stents, or nasobiliary drainage. 
Usually, in case of BDI, ERC can be performed electively, since timing of the 
endoscopic treatment has had no any effect on the final outcome (Adler et al., 
2017).  
The goal of endoscopic treatment in a biliary leak is to reduce the 
transpapillary pressure gradient. When transpapillary flow is improved by ES, 
stenting, or nasobiliary drainage, bile extravasation from the leak in the biliary 
tree will be reduced, allowing the leak to heal (Bjorkman et al., 1995, J. M. 
Dumonceau et al., 2018). Concomitant bile duct stones impair the bile flow, 
and they always need to be removed. The bile leak can be graded as low-grade 
(LG) if the leak of the contrast agent is visible in cholangiography from the 
distal part of the bile duct only after opacification of the intrahepatic ducts 
with balloon pressure. The bile leak is graded as high-grade (HG) if the 
contrast leak is visible before intrahepatic opacification (Sandha et al., 2004).  
Biliary postoperative strictures are treated by ERCP with dilatations and 
stents to re-establish the continuum of the bile duct, correct the pressure 
gradient, and enable the bile flow to the bowel (J. M. Dumonceau et al., 2018).  
Amsterdam type A leaks 
 
The European Society of Gastrointestinal Endoscopy (ESGE) guideline 
recommends endoscopic placement of plastic stents in the management of 
minor bile duct leaks to the total transection of the common bile duct or 
common hepatic duct (J. M. Dumonceau et al., 2018). Results of studies of 
Amsterdam type A leaks show a high (80-100%) success rate in treatment 
outcomes, but results of treatment method comparisons are controversial. 
Some studies have found stenting with or without ES superior to ES alone in 
all Amsterdam type A leaks (J. M. Marks et al., 1998, Kaffes et al., 2005, Dolay 
et al., 2010). One study found no difference in these treatment modalities 
(Mavrogiannis et al., 2006) and another study reported these treatments as 
equally efficient in LG Amsterdam type A leaks but not in HG Amsterdam type 
A leaks (Sandha et al., 2004). Plastic stents are the most commonly used stents 
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in the treatment of type A leaks. The length or size (7 or 10 French) of the stent 
do not influence the outcome (Katsinelos et al., 2008). If ES is chosen for the 
treatment, there is usually no need of further endoscopic procedures. Plastic 
stents always need to be removed in a second endoscopic session, usually after 
4-8 weeks in BDIs (J. M. Dumonceau et al., 2018). Biodegradable stents are 
the most recent innovation in stent development and in post-cholecystectomy 
BDIs. They are more expensive, but they do not need to be removed (Siiki et 
al., 2018).   
Amsterdam type B injuries 
 
Major biliary leaks with or without strictures are treated with stents to obtain 
an appropriate flow through the papilla and to bridge major lacerations of 
common or hepatic bile ducts (Bergman et al., 1996). Quite often, a simple 
plastic stent is not efficient enough for a high-output bile leak from the 
common or hepatic bile ducts, and filling the bile duct lumen with multiple 
plastic stents or FC-SEMSs is therefore a better treatment option (Luigiano et 
al., 2013, Canena et al., 2015). Plastic stents need to be removed or changed at 
scheduled intervals of 3 months, and metallic stents at intervals of 6-12 
months (Dumonceau et al., 2018). 
Amsterdam type C strictures 
 
Biliary strictures are treated successfully with balloon dilatations with 
multiple plastic stents or FC-SEMS. Usually, after 6-12 months of multiple 
plastic stents or FC-SEMS, a stricture is resolved (Costamagna et al., 2010a, 
Luigiano et al., 2013, J. M. Dumonceau et al., 2018). In difficult strictures, 
when passing the stricture with guidewire and instruments is impossible, the 
rendezvous technique with an interventional radiologist may be helpful 
(Gronroos, 2007). 
Amsterdam type D injuries 
 
Surgery is nearly always the primary treatment option for almost all type D 
injuries (Karvonen et al., 2007). In case of a total trans-section, it may be 
possible to re-establish the continuity of the injured common bile duct with 
the PTC-ERC combined rendezvous technique (Fiocca et al., 2011, Donatelli et 
al., 2014). 
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Operative treatment of biliary injury  
 
Most severe BDIs (Amsterdam type C and D) with disruption of the continuity 
of the main bile duct are treated operatively. The optimal surgical repair 
method depends on the type of BDI, the duration of the biliary obstruction, 
the degree of liver damage, the history of previous biliary repair surgery, and 
the patient’s general condition. Surgical repair options are an end-to-end 
choledocostomy, Roux-en-Y anastomosis between bile duct and jejunum, liver 
resections, and, in the most severe cases, hepatectomy and liver 
transplantation (Parrilla et al., 2014, Halbert et al., 2016). Referral of BDI 
patients to a hepatobiliary surgeon is highly recommended to avoid 
complications (Perera et al., 2011).  
 Outcome of the treatment of BDI 
 
The success rate of the endoscopic treatment of Amsterdam type A leaks has 
increased by up to 100% (Kaffes et al., 2005, Mavrogiannis et al., 2006). The 
treatment of an Amsterdam type B leak has traditionally been partly operative, 
and long-term results of endoscopic treatment are rare and come from small 
series. The success rate of Amsterdam type B leak has been reported to be 71%, 
or 3.3 times worse than when treating type A leaks (Bergman et al., 1996, 
Tewani et al., 2013). Treatment of BDI has changed in the direction of 
endoscopy and improved in the last 10 years with the availability of FC-SEMSs. 
Furthermore, results of the endoscopic treatment of Amsterdam type C BDI 
are scarce. One study of patients with a type C injury between 1991 and 2006 
reports a primary success rate in stricture treatment of 78%, reaching 91% 
after further ERCs (Vitale et al., 2008). Endoscopic treatment of benign biliary 
strictures of aetiologies other than BDI after cholecystectomy has been 
reported to have success rates of 85-94%. Recurrent stricture after endoscopic 
treatment occurs usually within 1 to 2 years but is treatable by ERC and 
stenting (Deviere et al., 2014, Tringali et al., 2016, Costamagna et al., 2010b). 
Late complications in stent treatment are stent clogging, with or without 
cholangitis and jaundice, or stent migration. However, these mild 
complications resolve quickly after stent exchange (Rauws, Gouma, 2004). 
Recurrent attacks of cholangitis have been reported in 3% of cases during a 5-
year follow-up (Boerma et al., 2001). 
The incidence of late postoperative stricture after hepaticojejunostomy is 
17-30%, and it usually appears within the first 2 years (Schmidt et al., 2005, 
Stilling et al., 2015). Risks in stricture development are multiple attempts of 
anastomosis repair, postoperative bile fistula, anastomosis of a non-dilated 
bile duct, T-drain site after surgery, associated vascular injury, and a highly 
situated injury in the biliary tree. If stricture leads to secondary biliary 
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cirrhosis, the patient may be a candidate for a liver transplant. (Schmidt et al., 
2005, Gad et al., 2018)  
2.1.3 ERCP ADVERSE EVENTS 
 
The most common complications after ERCP, with a total prevalence of 4-11%, 
are post-ERCP pancreatitis (PEP), bleeding during and after ERCP, 
cholangitis, and perforation (Cotton et al., 1991, Cotton et al., 2009, 
Vandervoort et al., 2002).  
Post-ERCP bleeding most commonly originates from biliary and/or 
pancreatic ES, with a rate of 0.3% to 2% (Freeman et al., 1996, Cotton et al., 
2009). Coagulopathy, active cholangitis, anticoagulant therapy within 3 days 
after ERCP, endoscopist case volume < 1 per week, and occurrence of bleeding 
during the procedure are risks for bleeding (Freeman et al., 1996). Balloon 
dilatation is a safer procedure than ES for patients with risks of bleeding  
Post-ERCP cholangitis occurs in 0.5% to 1.4% of ERCP cases (Cotton et al., 
2008, Ismail et al., 2012, Andriulli et al., 2007). Risk factors for cholangitis are 
combined percutaneous-endoscopic procedures, stenting of a malignant 
stricture, failed biliary access of drainage, incomplete stone removal, and 
previous liver transplantation (Freeman et al., 1996, Cotton et al., 2008).  
Post-ERCP perforation occurs in 0.08% to 0.6% ERCPs, with an 
associated 8% to 23% mortality rate (Cotton et al., 2009). Duodenal 
perforation by the endoscope, extramural guidewire passages, extension of the 
ES incision over the intramural segment of the bile or pancreatic duct, and 
stent migration may cause perforation and peritonitis.  
PEP is the most common and feared post-ERCP complication resulting from 
complex and multifactorial reactions in the pancreatic gland after pancreatic 
duct imaging and/or instrumentation (Cotton et al., 2009).  
2.1.4 RISK FACTORS AND PROPHYLAXIS OF PEP 
 
Prevalence of PEP varies in studies, depending on patient selection and the 
endoscopist’s competence, between 2% and 9%, and the prevalence of severe 
PEP between 0.3% and 0.6% (Freeman et al., 2004, Andriulli et al., 2007). 
Causes of PEP can be divided into procedure-related and patient-related 
mechanisms (Table 2). Procedure-related triggering factors are trauma (e.g. 
guide wire manipulation or ES, causing oedema and spasm leading to 
pancreatic duct obstruction), increased pancreatic duct pressure (due to 
contrast injection), and the inoculation of intestinal bacteria in the pancreatic 
duct (Rustagi et al., 2015). Patients with more than one risk factor have a 
significantly higher risk of PEP than those with a single risk factor (Freeman 
et al., 2001).  
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Table 2 Risk factors for PEP according to ESGE (J. Dumonceau et al., 2014) and 
literature 
 Odds ratios 
(95% confidence 
intervals) 
Incidence of PEP in 
patients with vs without 
risk factor 
Patient-related risk factors   
Definite risk factors   
Female gender 3.5 (1.1-10.6) 4.0% vs 2.1% 
Previous acute pancreatitis 2.46 (1.9-3.1) 6.7% vs 3.8% 
Suspected sphincter of Oddi dysfunction 1.91 (1.4-2.7) 8.6% vs 2.5% 
Likely risk factors   
Previous PEP 8.7 (3.2-23.9) 30% vs 3.5% 
Young age Range 1.1-2.9 6.2% vs 2.6% 
Non-dilated extrahepatic bile ducts  3.8% vs 2.3% 
Absence of chronic pancreatitis 1.9 (1.0-3.5) 4.0% vs 3.1% 
Normal serum bilirubin 1.9 (1.2-2.9) 4.1% vs 1.4% 
Procedure-related risk factors   
Definite risk factors   
Cannulation duration >10 minutes 1.8 (1.1-2.7) 10.8% vs3.8% 
Pancreatic guidewire passages >1 2.8 (1.8-4.3) 2.9% vs 9.5% 
Pancreatic injection 2.2 (1.6-3.0) 3.3% vs 1.7% 
Likely risk factors   
Pre-cut sphincterotomy 2.3 (1.4-3.7) 5.3% vs 3.1% 
Pancreatic sphincterotomy 3.1 (1.6-5.8) 2.6% vs 2.3% 
Large-balloon sphincter dilatation 4.51 (1.5-13.5) 9.3% vs 2.6% 
Failure to clear bile duct stones 3.4 (1.3-9.1) 1.7% vs 1.6% 
Intra-ductal ultrasound 2.41 (1.3-4.4) 8.4% vs 2.8% 
  
 
To prevent PEP, it is crucial to avoid unnecessary ERCPs by choosing correct 
indications and patients. The potential benefit vs the risk needs to be 
considered carefully. Some, often necessary, ERCP techniques increase the 
PEP rate, but a few technical strategies, such as guide wire cannulation, early 
pre-cut ES, pancreatic stent placement, and the double guide wire cannulation 
technique, may reduce attempts at cannulation and decrease the risk of PEP 
(J. Dumonceau et al., 2014, Gronroos et al., 2011). Clinical conditions, such as 
existing biliary ES, chronic pancreatitis, and malignancy in the head of the 
pancreas, are considered to protect against PEP (Loperfido et al., 1998, 
Freeman et al., 2001, Elmunzer, 2017). 
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 Pharmacological prevention of PEP 
 
Although patient- and procedure-related risk factors are well known and 
considered carefully, the PEP rate has not improved. Many pharmacological 
agents have been investigated in PEP prevention, but results have been 
disappointing. Tested agents such as glucagon (Silvis et al., 1975), calcitonin 
(Odes et al., 1977), nifedipine (Sand et al., 1993), octreotide (Arcidiacono et al., 
1994), and corticosteroids (Dumot et al., 1998, Zheng et al., 2008, Kubiliun et 
al., 2015) have been ineffective in PEP prevention. However, peri-procedural 
aggressive intravenous hydration with lactated ringer’s solution reduced 
53% of the PEP rate (Zhang et al., 2017) by enhancing pancreatic perfusion 
and tissue oxygenation, and optimising the pH level (Buxbaum et al., 2014). 
Somatostatin has been shown to have some effect in PEP prevention, but it 
is not recommended except in some selected cases (Wang et al., 2018). 
Nitroglycerin, as a smooth muscle relaxant, may lower sphincter of Oddi 
pressure and enhance pancreatic blood flow (Staritz et al., 1985). Some 
randomised clinical trials (RCTs) of nitroglycerin show reduced incidence of 
PEP, but the results are controversial and need more exploration (Kubiliun et 
al., 2015). Nafamostat is a protease inhibitor that inhibits trypsin and has 
been shown to reduce PEP by up to 60% (Yuhara et al., 2014). However, this 
is expensive and needs prolonged intravenous infusion (7-25 h) making its use 
problematic. In addition, the preventive effects of nafamostat on PEP in high 
risk cases are lacking (Kubiliun et al., 2015). Currently non-steroidal anti-
inflammatory drugs (NSAIDs) appear to be the most efficient and 
studied agents for PEP prevention (Yu et al., 2018). 
 NSAIDs in prevention of PEP  
 
It is thought that PEP develops due to a pro-inflammatory cascade originating 
from a pancreatic acinar cell injury. Phospholipase A2 is one of the key 
modulators on this cascade. NSAIDs are potent phospholipase A2 inhibitors 
as well as they also inhibit prostaglandin synthesis and neutrophil/endothelial 
cell attachment (Makela et al., 1997, Davies et al., 1997). Many studies have 
shown this inhibitory mechanism and the use of rectal NSAIDs (indomethacin 
and diclofenac) to reduce PEP in 40-70% of cases. Most of these studies were 
conducted within high risk patients (Elmunzer et al., 2012, Khoshbaten et al., 
2008, Otsuka et al., 2012, Sotoudehmanesh et al., 2007).  
Indomethacin has been superior to diclofenac in PEP prevention in 
separate RCTs, but no comparative study on these two agents has been 
undertaken. Only rectal NSAIDs have been effective in PEP prevention, and 
NSAIDs administered through other routes (oral, intramuscular, or 
intravenous) have been useless (Cheon et al., 2007, Park et al., 2015, de 
Quadros Onofrio et al., 2017). Rectal administration provides maximal drug 
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bioavailability, faster absorption and rapid concentration, suppressing the 
inflammatory responses of PEP. The oral route has a different metabolism 
from the rectal route due to gastro-hepatic circulation, which explains 
NSAIDs’ ineffectiveness in PEP prevention. The reason intravenously or 
intramuscularly administered NSAIDs are powerless in PEP prevention is 
unclear (Lyu et al., 2018). ESGE guidelines suggest routine use of rectal 
NSAIDs for all ERCP patients without contraindications. This 
recommendation is based on 6 meta-analyses (J. Dumonceau et al., 2014).  
 Pancreatic stent placement in prevention of PEP  
 
ERCP-induced papillary oedema may increase pressure within the pancreatic 
duct. Pancreatic stent placement is thought to reduce this pressure and 
decrease the risk of PEP development (Tarnasky et al., 1998, Fogel et al., 
2002). Controversially, the stent placement may enhance the risk of PEP, 
especially if stent placement is attempted but remains unsuccessful (Freeman 
et al., 2004). A pancreatic stent is therefore recommended only in cases of 
difficult cannulation in patients with a high risk of PEP (J. Dumonceau et al., 
2014). 
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2.2 ACUTE PANCREATITIS (AP) 
2.2.1 EPIDEMIOLOGY AND AETIOLOGY OF AP 
 
Acute pancreatitis (AP) is one of the most common gastrointestinal disorder 
globally. In Finland, the incidence of AP has been the highest in Europe, 73-
102/100,000 (Jaakkola et al., 1993, Pelli et al., 2009). During recent decades, 
the trend of AP worldwide has been increasing (Roberts et al., 2017, Krishna 
et al., 2017), but a recently published survey from the United States shows 
stabilisation, and even a decrease for the first time, in the incidence of AP 
(Sellers et al., 2018). Although AP related mortality has decreased to 0.79% 
due to better diagnostics for the disease (Krishna et al., 2017), in severe AP 
(SAP) it is still as high as 20-42% (Harrison et al., 2007, Pavlidis et al., 2013, 
Karjula et al., 2017). APs induced by different aetiological factors, e.g. biliary 
stones, alcohol, and hypertriglyseridemia, do not differ in mortality rates 
(Andersen et al., 2008, Goyal et al., 2016). 
 
Table 3  Aetiology of AP 
Toxic: 
Alcohol 
Medicines 
Drugs 
Tobacco 
Viruses 
Parasites 
Genetic mutation in: 
CFTR 
PRSS1 
PRSS2  
CTRC  
CASR  
      SPINK1 
Obstructive: 
Cholelithiasis 
Papillary tumours 
Duodenal diseases 
Pancreas divisum 
Sphincter Oddi dysfunction 
Traumatic: 
ERCP 
Penetrating and blunt injuries 
Surgery 
      Pancreatic biopsy 
Endocrine/metabolic: 
Hypertriglyseridemia 
      Hypercalcemia  
Other: 
      Idiopathic 
      Autoimmune diseases 
 
There are regional variations in the aetiology of AP, related to alcohol 
consumption habits and the prevalence of gallstones. In southern Europe, 
gallstones are the dominant reason for AP (Roberts et al., 2017), whereas in 
Finland, alcohol causes about 70% and gallstones 20% of AP cases (Halonen 
et al., 2000, Jaakkola et al., 1993, Karjula et al., 2017). Alcohol-related AP is 
more common in men than in women, but with similar consumption habits 
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this difference disappears (Lankisch et al., 2002). In addition to ethanol and 
gallstones, AP has a variety of other aetiologic factors, and 10% of AP cases 
remain idiopathic (Table 3). Some of the idiopathic APs are explained by under 
3 mm gallstones that are radiologically poorly visible in papilla Vateri or 
gallstones that have already passed through the papilla, inducing AP (Raty et 
al., 2015). Old age, obesity, and a meat-rich diet are factors that have been 
associated with an increased risk of AP (Yadav et al., 2013, Dugum et al., 2018). 
Alcohol-induced AP patients are prone to hospital re-admissions compared 
with patients with other aetiologies (44% vs 22%, respectively) (Karjula et al., 
2017). 
2.2.2 PATHOGENESIS OF AP 
 
The pathogenesis of AP has been widely researched, but the exact mechanism 
remains unresolved. Pancreatic exocrine glands consist of acinus formed of 
digestive enzymes secreting acinar cells. Pancreatic ducts formed of ductal 
cells secrete 2.5 l/day of alkaline HCO3--rich fluid, which neutralises acidic 
content secreted by acinar cells. Ducts provides a structural framework for the 
pancreas. They also convey digestive enzymes from acinar cells (M. G. Lee et 
al., 2012). Pancreatic secretion is regulated by hormonal and neural 
stimulation, mediated by secretin and cholecystokinin (Chandra et al., 2012). 
Stellate cells surrounding acinar and ductal cells are thought to play a key role 
in the repair and recovery of the gland (Apte et al., 2012). Multiple triggering 
factors initiate pancreatic inflammation in acinar, ductal, and stellate cells.  
Alcohol directly affects the pancreatic acinar, ductal, and stellate cells, 
increasing the cytosolic calcium concentration, which triggers the 
inflammatory process of AP. Ethanol is metabolised via an oxidative or a non-
oxidative pathway, producing toxic metabolites (acetaldehyde and fatty acid 
ethyl esters) that tend to injure the pancreas (Haber et al., 1998, Gukovskaya 
et al., 2002, Apte et al., 2010). In acinar cells, alcohol metabolism causes 
increased synthesis of digestive and lysosomal enzymes, enhancing their 
potential contact and premature activation (Norton et al., 1998). Alcohol also 
induces bacterial leak from the bowel into the pancreas, and this has been 
shown to be one of the triggering factors for AP (Vonlaufen et al., 2007). 
Although the risk of AP is known to increase with heavy alcohol use, only some 
heavy drinkers develop symptomatic AP (Durbec et al., 1978, Steinberg et al,. 
1994). Additional factors to alcohol are needed to initiate AP, but this 
mechanism remains unclear. Bile acid reflux has also been shown to have 
direct effects on ductal, acinar and stellate cells (Hegyi et al., 2015, Kim et al., 
2002, Ferdek et al., 2016). Both bile acids and ethanol in high concentrations 
inhibit ductal HCO3- secretion and increase cytosolic calcium concentration. 
A decreased extracellular pH enhances both trypsinogen auto-activation in the 
pancreatic ducts and injury in acinar cells (Maleth et al., 2011). Biliary stones, 
tissue swelling after ERCP, a tumour, or pancreatic stones can cause 
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pancreatic duct obstruction, leading to an upstream blockage of pancreatic 
secretion and the inhibition of the exocytosis of digestive enzymes initiating 
AP (J. Dumonceau et al., 2014, Mujica et al., 2000).  
Regardless of the aetiology of AP, the inflammation reaction is quite 
similar. The progression of the disease has three steps: local pancreatic 
inflammation seen in mild AP; general systemic inflammatory response 
syndrome (SIRS); and multiple organ failure in SAP (Bhatia et al., 2005).  
 Calcium signalling 
 
Short-lasting physiological local calcium signals control normal fluid and 
enzyme secretion in acinar cells. Bile acids, alcohol metabolites, and low 
extracellular pH levels increase calcium release within acinar cells, leading to 
persistent high cytosolic calcium concentrations (Petersen et al., 2006, 
Petersen et al., 2009, Reed et al., 2011). Excessive intracellular calcium 
triggers trypsinogen activation within the acinar cells. It also leads to oxidative 
stress, resulting in necrosis (Mukherjee et al., 2008). A high calcium level also 
activates nuclear factor κB (NF-κB), which plays a key role in developing 
acinar cell damage and SIRS (Gerasimenko et al., 2014). Recently, calcium 
signalling has been shown also to occur in stellate cells. Dying acinar cells 
release trypsin, which increases calcium concentration in stellate cells, leading 
to the production of nitric oxide. It in turn diffuses to the acinar cells, 
promoting the necrotic process and creating a vicious circle of necrotic acinar 
cell death (Gryshchenko et al., 2018). 
 Nuclear factor κB  
 
NF-κB is a signalling molecule responsible for regulating the production of a 
variety of mediators involved in immunity and inflammation: chemokines, 
cytokines, and adhesion molecules recruit inflammatory cells to the site of 
inflammation (Sen et al., 1986, Baldwin, 1996). In the early stage of AP, intra-
acinar activation of NF-κB directly triggers the inflammatory pathway, causing 
SIRS, and worsens the severity of AP. Anti-inflammatory agents have been 
shown to be effective inhibitors of pancreatic NF-κB activation in 
experimental AP (Rakonczay et al., 2008, H. Huang et al., 2013). Although 
acinar NF-κB and trypsinogen activation occur with similar time and are both 
induced by increased intracellular calcium concentration, they are 
independent events (Dawra et al., 2011). 
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 Trypsinogens 
 
The pancreas secretes digestive enzymes as inactive precursors in acinar cells. 
Trypsinogens are the most important digestive proenzymes of the proteins in 
pancreatic juice. In normal conditions, the acinar cell is protected from 
enzymatic damage by secreting digestive enzymes as inactive forms 
(zymogens), storing the enzymes inside membrane-bound compartments, 
synthesizing and releasing trypsin inhibitors simultaneously with the 
zymogens, maintaining low intracellular calcium concentrations favouring 
trypsin degradation, and maintaining the acidic pH inside the zymogen 
granules, which inhibits trypsin activity (Gorelick et al., 2009).  
     Pancreatic secretory trypsin inhibitor (PSTI), also called Kazal-type trypsin 
inhibitor (SPINK1) after the only gene encoding it, was first identified in urine 
in ovarian cancer patients and called tumour-associated trypsin inhibitor 
(TATI) (Huhtala et al., 1982, Stenman et al., 1982). SPINK1 prevents 
premature activation of trypsinogens within the acinar cells in normal 
conditions (Pubols et al., 1974). In normal conditions, only a minority of 
trypsinogens leak into the circulation, where the trypsin inhibitors (alpha-1-
antitrypsin and alpha-2-macroglogulin) deactivate active trypsin (Borgstrom 
et al., 1978a).  
As early as1896, Hans Chiari proposed that premature activation of 
trypsinogens in acinar cells led to AP. This theory has since been frequently 
studied in experimental and clinical pancreatitis. Although many details have 
been solved, the exact mechanism of AP pathogenesis has remained obscure. 
Intra-acinar hyper-concentration of calcium triggers intracellular premature 
activation of trypsinogen (A. U. Shah et al., 2009) and cathepsin B, a lysosomal 
hydrolase, serving as a mediator in this process (Van Acker et al., 2002). If the 
activation of trypsin exceeds the intra-acinar trypsin inhibition system, it 
results in the release of pancreatic enzymes, eventually causing acinar cell 
damage and death. This process is responsible for half of pancreatic necrosis. 
Acinar cell damage leads to release of damage-associated molecular patterns 
(DAMPs), an overdose of which in turn activates cytokine production and 
inflammation cell recruitment (Martinon et al., 2009). Trypsin has also been 
found to be a triggering factor for stellate cells to join AP pathogenesis 
(Gryshchenko et al., 2018). 
 Human pancreatic juice contains three trypsinogens with different 
isoelectric points. The first trypsinogens found were cationic trypsinogen-1 (T-
1) and anionic trypsinogen-2 (T-2) (Figarella et al., 1969). A third minor 
trypsinogen (mesotrypsinogen, trypsinogen-3 [T-3]) with intermediate 
electrophoretic mobility was found 10 years later (Rinderknecht et al., 1984). 
Trypsinogens also appear in extrapancreatic tissues: vascular endothelial 
cells; skin; the oesophagus; the stomach; the small intestine; the lungs; the 
kidneys; the liver; the bile ducts; the spleen; and neuronal cells (Koshikawa et 
al., 1998).  
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T-1 and 2 represent about 19% of the proteins in pancreatic juice. 
Concentrations of T-1 are twice those of T-2 (Figarella et al., 1969). The 
average concentration of T-1 and T-2 is 15-26 μg/l (Borgstrom et al., 1976, 
Florholmen et al., 1984) and 5.5 μg/l (Largman et al., 1978) respectively. 
ERCP-induced pancreatitis studies have shown that serum T-1 and T-2 levels 
increase 10-fold as early as 2 h after ERCP, and the levels reach their peak in 
6 h. T-1 concentration decreases within 48 hours of the onset of the disease, 
whereas T-2 concentrations remain elevated for several days (Kemppainen, et 
al., 2005).  In alcohol-induced AP, T-2 is more elevated than T-1, whereas in 
biliary-induced AP, the ratio is contrary. This has been shown to be helpful in 
discriminating between biliary- and alcohol-induced pancreatitis (Andersen et 
al., 2001). 
 
T-3 is the minor isoenzyme, occurring in low concentrations in pancreatic 
juice, where it represents only 0.5% of the proteins (Rinderknecht et al., 1984). 
SPINK1 cannot inhibit T-3 as it can T-1 and T-2, but T-3 can digest SPINK1 
instead (Szmola et al., 2003). As well as T-1 and -2, T-3 concentration rises in 
AP patients. In healthy individuals the concentration of T-3 is 1-4.4 μg/l, 
whereas in mild AP the median concentration is 9.5 μg/l, and in severe 15 μg/l. 
However, T-3 has not been found effective in predicting the severity of AP 
(Oiva et al., 2011). 
 
A complex between trypsin-2 and α?-antitrypsin (Trypsin-2-AAT) 
is formed when α?-antritypsin, one of the major human circulating trypsin 
inhibitors, inactivates trypsin-2 which escapes into the circulation. Normally, 
enterokinase inactivates trypsinogens in the duodenum (Borgstrom, Ohlsson, 
1978b). Trypsin-2-AAT serum level increases more slowly than T-1 or T-2, and 
in severe AP cases it increases for up to 5 days (Kemppainen et al., 1997, 
Lempinen et al., 2005). The complex has been shown to be more accurate than 
T-2, C-reactive protein (CRP), or amylase in the diagnosis of AP and in the 
assessment of the severity of AP (Hedstrom et al., 1996, Lempinen et al., 
2003). The ratios between T-1 and trypsin-2-AAT may help in recognising 
alcohol-induced AP (Andersen et al., 2001). 
 
SPINK1 is synthesised in pancreatic acinar cells, and it is secreted with 
trypsinogens and other digestive enzymes (Rinderknecht, 1986).  It represents 
0.1-0.8% of the total protein of pancreatic juice, and its main function is to 
prevent and defend against premature activation of trypsinogens in 1:1 molar 
ratio (Pubols et al., 1974, Rinderknecht, 1986). Mutation in the SPINK1 gene 
is more common in patients with AP compared to the general population 
(Whitcomb, 1999). 
SPINK1 is known to behave as an acute phase reactant, and in addition to 
pancreatic origin, it has also been detected in the liver, brain, spleen, lung, 
kidney, stomach, small intestine, duodenum, colon, appendix, gallbladder, 
urinary tract, ovary, prostate, and breast (Itkonen et al., 2014). SPINK1 as 
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TATI, is a useful biomarker for diagnostic and prognostic purposes, 
particularly in ovarian cancer, but in many other cancers too (Huhtala et al., 
1982, Stenman, 2002). Serum concentrations of SPINK1 in the normal healthy 
population are 3-16 μg/l. Due to its small molecular size, its half-life in the 
circulation is only 6-8 mins (Eddeland et al., 1978b, Marks et al., 1983). In AP, 
inflammation and necrosis leads to a leakage of SPINK1 into the circulation 
and urine, increasing SPINK1 concentrations up to 100-fold (Eddeland et al., 
1978a, Hedstrom et al., 1996a).  
 
Figure 1  Inflammation in AP arising in acinar and stellate cells. Acinar cells respond to 
pathologic insult, activating NF-κB and leading to the production of cytokines and 
other mediators that initiate the inflammatory response. Trypsinogen activation 
causes cell death and the release of damage-associated molecular patterns 
(DAMPs) from damaged cells, which activates inflammasomes. The inflammatory 
mediators recruit neutrophils, macrophages, and T-cells into the pancreas, leading to 
a cytokine storm and a systemic inflammation reaction (SIRS), and multiple organ 
dysfunction (MODS). Trypsin also causes an increase in calcium levels in stellate 
cells, triggering the production of nitric oxide, enhancing further acinar cell damage. 
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 Inflammation of AP 
 
Inflammation is a protective physiological immune system response to tissue 
injury, which aims to eliminate damaged cells and initiate tissue repair. 
Immune responses work as part of a network of cellular and humoral 
responses. Secreted mediators, cytokines and chemokines, coordinate the 
inflammatory cells (monocytes, macrophages, polymorphonuclear leucocytes, 
eosinophils, basophils, mast cells, T- and B-cells, and natural killer cells). 
(Gukovsky et al., 2013)  
Pancreatic enzymes cause local destruction in acinar cells, and injured 
acinar cells activate numerous inflammatory pathways. Activated NF-κB 
produces cytokines, causing a cytokine storm, which in turn recruit 
neutrophils, macrophages, monocytes and lymphocytes to the pancreas 
(Baldwin, 1996). Activated trypsin causes cell death and damage, and 
damaged necrotic cells release DAMPs and other molecules, which also 
activates multiple inflammatory pathways, leading to the production and 
release of inflammatory cytokines, interferons, chemokines and cell adhesion 
molecules to the inflammation sites and increasing the inflammation and the 
severity of AP (Hoque et al., 2012)(Figure 1). 
Several studies have shown an association between cytokines and chemokines 
with remote OD and suggest that systemic complications during AP result 
from an uncontrolled activation of an inflammatory cascade (Aoun et al., 
2009, Ueda et al., 1996, Espinosa et al., 2011, Muller et al., 2000, Nieminen et 
al., 2014). An excessive stimulation of the inflammatory cascade causes early 
systemic complications and SIRS, within the first week of AP (Table 4). In the 
early course of AP, infections are rare, and necrosis is sterile.  However, during 
SIRS, there is a higher risk of complicated AP and organ failure (Mayer et al., 
2000, Bone, 1996a, Rangel-Frausto et al., 1995). Persistent SIRS, lasting over 
a week, leads to mixed inflammatory response syndrome (MARS) and further 
to the compensatory anti-inflammatory response syndrome (CARS). At this 
point of the inflammation process, pro-inflammatory and anti-inflammatory 
mediators battle in a micro-environment, often resulting in an unbalance and 
the finding of both pro- and anti-inflammatory mediators in the circulation 
(MARS) (Phillip et al., 2014). If the mediators achieve balance, homeostasis is 
restored. Without balance, eventually either a massive SIRS or CARS will 
ensue. During CARS, the immune system is downregulated, and general 
infections, as well as infections of pancreatic or peripancreatic necrotic tissues, 
are more frequent. During SIRS, a predomination of cardiovascular problems, 
apoptosis, and organ dysfunction is apparent. (Bone, 1996b) (Figure 2)   
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Figure 2 Phases of severe pancreatitis. CARS: compensatory response syndrome, 
SIRS: systemic inflammatory response syndrome 
 
 
 
 
 
 
 
Table 4 Criteria of systemic inflammatory response syndrome; two or more present 
criteria defines SIRS (Bone, 1992) 
Heart rate >90 beats/min 
Core temperature <36 ºC or > 38 ºC 
White blood count <4 x 109 /L or > 12 x 10/L or > 10% immature forms 
Respiratory rate >20/min or PCO2 < 32 mmHg 
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 Complications of AP 
 
The course of AP may cause local and remote complications. Local 
complications appear in pancreas parenchyma and surrounding tissue as 
peripancreatic fluid collections, and pancreatic or peripancreatic necrosis. 
During AP, the fluid collections and necrosis can develop to pseudocysts and 
walled-off necrosis (WON) (Sarr et al., 2013). SIRS caused by excessive 
stimulus of cytokines generates remote complications in renal, respiratory and 
cardiovascular organ systems. Organ dysfunction (OD) develops in 40% of 
patients with AP, and in SAP it has been associated with increasing mortality 
(Buter et al., 2002). According to the Modified Marshall Score (MMS) the 
presence of organ dysfunction (OD) is identified if the calculated organ failure 
score is 2 or more and the failure affects one or more of the respiratory, renal 
and/or cardiovascular organ systems. The criteria for scoring the OD are 
presented in Table 5 (Marshall et al., 1995). 
 
Table 5  Modified Marshall Score (Marshall et al., 1995) 
 Score     
Organ system 0 1 2 3 4 
Respiratory 
(PaO2 / FiO2) 
> 400 301-400 201-300 101-200 ≤ 101 
Renal (serum 
creatinine 
μmol/l) 
≤134 134-169 170-310 311-439 > 439 
Cardiovascular 
(systolic blood 
pressure, mm 
Hg) 
> 90 < 90, fluid 
responsive 
< 90, not fluid 
responsive 
< 90, pH < 7.3 < 90, pH < 7.2 
 
2.2.3 DIAGNOSIS OF AP 
 
The diagnosis of AP requires two of three diagnostic features: 1) abdominal 
pain; 2) serum or plasma amylase or lipase concentrations at least three times 
greater than the normal upper limit; and 3) characteristic findings of AP from 
abdominal imaging (CECT or MRI, rarely US). Radiological examinations 
should be reserved for patients whose diagnosis is unclear, who fail to improve 
clinically within the first 48-72 h, or have possible complications (Banks et al., 
2006, Tenner et al., 2013). 
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 Clinical symptoms  
 
The main symptom of AP is usually severe and persistent epigastric abdominal 
pain resembling peritonitis. The pain intensity varies without reflecting the 
severity of the disease. In gallstone-induced AP, the onset of the pain can be 
sudden and knife-like, and may radiate to the back. In alcohol-induced, 
hereditary or metabolic AP, the onset may be less abrupt. Additional 
symptoms are nausea, vomiting, fever, tachycardia, dyspnoea and abdominal 
distension, as well as hemodynamic instability in severe cases (Whitcomb, 
2006, Banks et al., 2006). Most patients arrive at hospital within 12-24 h after 
the onset of symptoms. Cutaneous manifestations, e.g. Cullens sign in the 
abdomen and flank areas, produced by tracking of liberated pancreatic 
enzymes to the subcutaneous spaces, are rarely seen signs that indicate a 
severe form of and poor prognosis for AP (Meyers et al., 1989, Fox, 1966, 
Sigmund et al., 1954, Lankisch et al., 2009). 
 Laboratory tests 
 
The measurement of amylase and lipase has been central in the diagnosis of 
AP. Amylase is pancreas- and salivary gland-produced glycoside hydrolase, 
and it can be found in other tissues in lower concentrations. Amylase increases 
rapidly in blood within 3-6 h of the onset of AP. Due to its short half-life (10-
12 h), amylase decreases rapidly and the kidneys excrete it completely within 
3-5 days (Pieper-Bigelow et al., 1990, Shah et al., 2010). Hyperamylasemia 
occurs in several other conditions besides AP: pancreatic diseases and 
traumas, burns, salivary diseases, gastrointestinal disorders, hepatitis, 
cirrhosis, gynaecological disorders, cholecystitis, peritonitis, biliary calculus, 
chronic alcoholism, renal failure, acidosis, pregnancy, head injuries, multiple 
osteomas, and aortic dissection (Yegneswaran et al., 2010).  
Serum lipase rises rapidly 3-6 h after the onset of AP and peaks within 24 
h, remaining in the blood longer and at higher concentrations than amylase. 
Since lipase is primarily synthesised in the pancreas it is more specific for AP 
than amylase (Shah et al., 2010). Sometimes lipase can be detected during 
inflammatory bowel disease, intestinal ischemia, malignancies, fat embolism, 
oesophagitis, and liver and renal failure (Viljoen et al., 2011). Many 
recommendations prefer lipase over amylase in the diagnosis of AP. However, 
a meta-analysis by Cochrane Library found no difference between these tests 
(Lippi et al. 2012a, Rompianesi et al., 2017). 
Specific assays for T-1, T-2, and T-3 have been developed, but the 
complexity and cost of the tests have hampered their use (Itkonen et al., 1990, 
Oiva et al., 2011). A rapid dipstick test for urine T-2 (Actim Pancreatitis; Medix 
Biochemica, Kauniainen, Finland) was developed 20 years ago (Hedstrom et 
al., 1996). The test is easy and quick to use; after dipping in the fresh urine 
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sample, the result is detectable within 5 minutes. The dipstick test has a 
detection line as well as a reference line. Both turn blue if the urine T-2 
concentration exceeds 50 ?g/l, indicating a positive dipstick test. This has 
been shown to be a reliable diagnostic test for AP and PEP (Kemppainen et al., 
1997, M. Kylanpaa-Back et al., 2000). In a Cochrane Library meta-analysis the 
T-2 dip stick test performed equally in AP and PEP diagnosis to serum amylase 
and lipase: 10% of cases were diagnosed as positive incorrectly; 25% of cases 
were not diagnosed with any of the tested markers (Rompianesi et al., 2017). 
The serum concentrations of amylase or lipase do not correlate with the 
severity of the disease. Instead, CRP, a complete blood count, electrolytes, 
creatinine, blood glucose, liver transaminases, coagulation status, alkaline 
phosphatase, and total albumin should be measured and repeated during the 
clinical course (Lankisch et al., 2015). 
 Radiological examinations 
 
CECT with both intravenous and oral contrast agents is the standard imaging 
technique for the evaluation of AP and its complications (Balthazar et al., 1990, 
Balthazar, 2002a). Typically in AP, CETC shows focal or diffuse enlargement 
of the pancreas, an irregular contour of the margins, an increased density of 
peri-pancreatic fat planes and a thickening of fascial planes, and the presence 
of intraperitoneal or retroperitoneal fluid collections (Balthazar, 2002b). A CT 
scan can confirm the AP diagnosis, but it is rarely necessary on admission to 
hospital if an AP diagnosis is clear. However, if the patient is unstable and does 
not improve within 48-72 h, a CT scan should be performed to explore possible 
complications.  
Based on the CECT scan, AP can be classified as interstitial oedematous 
pancreatitis or necrotic pancreatitis. Interstitial oedematous AP is a common 
finding in mild AP, representing 90-95% of all pancreatitis, and it is 
characterised by localised or diffuse enlargement of the pancreas (Sarr et al., 
2013). Pancreatic necrosis lacks enhancement after intravenous contrast 
administration because of thrombosis of pancreatic microcirculation. It can 
usually be detected in CECT 96 h (sometimes even 48 h) after the onset of the 
disease (Isenmann et al., 1993). Necrotising AP may be sterile or infected (Sarr 
et al., 2013). The pancreatic necrosis findings in CECT can be categorised in 
three groups: 1) encapsulated organised pancreatic necrosis and necrotic 
peripancreatic fat; 2) central gland necrosis, resulting in the disruption of the 
pancreatic duct and persistent collections; 3) extra-pancreatic necrosis 
without pancreatic necrosis (Bharwani et al., 2011). 
MRI is an alternative examination modality if CECT is contraindicated due 
to a contrast allergy or renal dysfunction. The morphological alterations in 
MRI in AP are very similar to those in CECT (Lecesne et al., 1999). However, 
MRI distinguishes necrosis in fluid collection better than CECT (Morgan et al., 
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1997, Sarr et al., 2013). MRI is superior to CECT in diagnosing biliary stones 
in the common bile duct (S. L. Lee et al., 2018).  
Transabdominal US is cheap and widely available, but there are 
limitations to its use. US can reveal an enlarged pancreas as a result of oedema, 
but the accuracy is poor in obese patients or when intestinal gas is present. A 
normal finding does not therefore rule out a diagnosis of AP (Bortoff et al., 
2000).  
 Classification 
 
The severity of AP varies from a mild, sometimes subclinical disease, to severe 
AP (SAP) with OD and even lethal consequences. Patients with mild AP 
recover spontaneously within a few days, but patients with SAP may develop 
life-threatening local and/or systemic complications. The Atlanta symposium 
created a classification system in 1992, and it has since been the standard 
classification for the severity of AP (Bradley, 1993). The classification has been 
revised over the years because of a better understanding of organ dysfunction 
and pancreatic morphological changes (Revised Atlanta Classification). 
Currently, AP is classified as a mild, moderately severe or severe disease (Table 
6) (Sarr et al., 2013). Severity is assessed with CECT, showing possible local 
morphologic complications, and MMS revealing the presence of OD.  
In mild AP, OD and local systemic complications are absent, patients are 
usually discharged in early phase of the disease and they do not require 
pancreatic imaging. In moderately severe AP, transient OD (resolves within 48 
h) or local peri-pancreatic collections are present. SAP is characterised by 
persistent OD, which can affect single or multiple organ systems. Patients with 
persistent OD usually have one or more local complications. An early onset of 
OD increases the risk of death to 36-50% (Johnson et al., 2004, Mofidi et al., 
2006, Buter et al., 2002). 
 
Table 6 Revised Atlanta Classification (Sarr, Banks et al. 2013)  
 Organ dysfunction Local complications Systemic 
complications 
Mild  
pancreatitis 
- -  - 
Moderately severe 
pancreatitis 
Transient (resolves 
< 48 h) 
+/- +/- 
Severe pancreatitis Persistent  
(> 48 h) 
+/- +/- 
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 Severity assessment  
 
The course of AP varies, and the development of organ dysfunction is the most 
important determinant for the outcome of AP. To provide optimal care for 
those in need, it is crucial to distinguish between patients in developing 
intensive care requiring SAP. Several scoring systems and laboratory tests 
have been the interest of studies of the optimal severity assessment in the early 
phase of the disease.  
 
Clinical scoring  
 
Several clinical scores can be calculated from physiology, laboratory, and 
occasionally radiological parameters to describe the severity of AP and predict 
the course of the disease. One of the first scoring systems was the Ranson 
score, originating in 1974 with high sensitivity (84 %) and specificity (78 %) 
evaluated 48 h after admission (Ranson et al., 1974). Many additional scoring 
systems, such as Acute Physiology and Chronic Health Evaluation II (APACHE 
II), the Bedside Index for Severity in Acute Pancreatitis, the Harmless Acute 
Pancreatitis Score, the Glasgow-Imrie Criteria, the Pancreatic outcome 
Prediction, and the Revised Japanese Severity Score, have since been 
developed, but these scoring systems attempt to differentiate only severe 
cases, and none has been sufficiently accurate to differentiate between  
transient and persistent OD (Mounzer et al., 2012). Most of these scoring 
systems are completed at the earliest 24-48 h after admission and are quite 
complicated to use, requiring several measurable variables. 
 
Laboratory measures and biomarkers 
 
A variety of laboratory tests has been studied as a predictor for the developing 
of OD. Routinely used tests such as serum creatinine, haematocrit, and 
calcium reflect the presence of OD and measure intravascular volume 
depletion rather than predicting OD development.  A rising creatinine level 
unresponsive to fluid administration indicates a risk of SAP, and a creatinine 
level of ≥ 159 μmol/l 48 h predicts the development of pancreatic necrosis 
(Lipinski et al., 2013, Muddana et al., 2009, Mofidi et al., 2006). Hematocrit 
≥ 44% at admission predicts SAP, and hematocrit ≤ 44% has a strongly 
negative predictive value (Brown et al., 2000). Hypocalcemia is caused by 
cathecolamine-mediated calcium translocation from plasma into tissues 
(Shahbaz et al., 2011). Low calcium levels on admission to hospital have been 
shown to predict SAP and indicate persistent OD (Mentula et al., 2005a, Peng 
et al., 2017).  
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Inflammatory markers  
 
Major acute phase protein CRP is most frequently used in the prediction and 
evaluation of the severity of AP (Puolakkainen et al., 1987, Mofidi et al., 2009). 
Inflammatory stimuli trigger CRP production in hepatocytes with a delay of 
up to 72 h, which impairs its use in the early phase of the disease. CRP is 
unspecific, and it also reflects other inflammation conditions. However, it is 
shown that CRP > 200 mg/L 48 h after the onset of symptoms is highly 
predictive of pancreatic necrosis, and CRP > 150 mg/L 48 h after the onset of 
symptoms can be associated with SAP (Al-Bahrani et al., 2005, Puolakkainen 
et al., 1987). 
Serum procalcitonin (PCT) is a precursor of thyroid hormone calcitonin. 
In healthy adults, it is undetectable. All tissues have the potential to produce 
PCT, and it is elevated in patients with sepsis and severe inflammation (Becker 
et al., 2010). Pancreatic necrosis is associated with inflammation, and 
detectable PCT reflects the complicated course of AP and the need for 
radiological examination. PCT is already measurable within hours of symptom 
onset, and it has been found in significantly elevated concentrations in 
patients with infected pancreatic necrosis and associated ODs or death (M. L. 
Kylanpaa-Back et al., 2001b, Rau et al., 2007a). 
Soluble urokinase-type plasminogen activator receptor (suPAR) is a 
systemic inflammation marker which increases in many conditions such as 
inflammation and infection but also in hypoxemia and ischemia in the early 
stage. It has been shown to predict the outcome of critical illnesses and the 
development of SAP and lethal AP (Nikkola et al., 2017, Lipinski et al., 2017). 
However, as a systemic inflammation marker, suPAR is not specific for AP, 
which affects its use as a predictive tool. 
 Pentraxin 3 is also an acute phase protein in which plasma concentrations 
increase rapidly in inflammatory conditions. Various cells in peripheral tissue 
produce Pentraxin 3, and this is shown to predict severe sepsis and a fatal 
outcome in critically ill patients (Uusitalo-Seppala et al., 2013) and in the 
severe form of AP (Simsek et al., 2018). 
Since cytokines are elevated in the early course of pancreatitis, they have 
been studied as predictors of OD. Interleukins such as IL-6, IL-8, IL-10, and 
hepatocyte growth factor have been found to best predict severe AP among 
cytokines (Ueda et al., 1996, Mentula et al., 2005b, Aoun et al., 2009). In 
patients without OD at admission, IL-6, IL-8, and HGF have been found to 
predict severe AP (Nieminen et al., 2014, Jain et al., 2018). In some clinics, IL-
6 is used to identify patients at risk of developing severe disease (Rau et al., 
2007b). In addition, other cytokines e.g. such as IL-1β, IL-12, IL-15, IL-17, IL-
2 receptor, IL-1 receptor antagonist, growth-related oncogene alpha, 
Macrophage migration factor, and granulocyte macrophage colony 
stimulating factor have also been studied and found to predict SAP with 
varying results.   
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Among the other inflammatory markers examined for the severity 
assessment of AP are e.g. CD73/ecto-5´nucleotidase, an adenosine-generating 
enzyme which dampens inflammation (Maksimow et al., 2014), CD11b, an 
adhesion molecule of neutrophils and monocytes (M. L. Kylanpaa-Back et al., 
2001a), complement regulator protein CD59 (Lindstrom et al., 2008), and 
extracellular matrix degradation endopeptidases matrix metalloproteinase 8 
and 9 (Nukarinen et al., 2016). 
 
Markers of pancreatic injury 
 
The most studied trypsinogen activation marker are T-2 (Sainio et al., 1996a, 
Hedstrom et al., 1996) and trypsin-2-AAT, which have shown marked 
correlation with complicated AP. They have also been shown to be superior to 
T-1 in diagnosing AP (Hedstrom et al., 1996, Hedstrom et al., 2001). SPINK1 
concentration is also known to increase in AP in accordance with its severity, 
but it has not been studied in the prediction of the development of OD 
(Kitahara et al., 1980, Ogawa, 1988a, Lempinen et al., 2005). Trypsin 
activation peptide TAP is a peptide released from trypsinogen during the 
activation of trypsin from trypsinogen in severe AP (Formela et al., 1995). 
When measured from urine, it is shown to be as useful in the assessment of 
the severity of AP (Neoptolemos et al., 2000, W. Huang et al., 2013, Yasuda et 
al., 2019).  
Carboxypeptidase B Activation Peptide is a trypsin activation peptide 
which has been shown to be rapidly released into the circulation and urine 
after the onset of AP. It has been shown to be useful in the prediction of the 
severity of AP measured from both blood and urine (Deng et al., 2015). 
Cell death markers such as circulating DAMPS have also been investigated 
in the assessment of SAP. It has been shown that nucleosomes predict SAP 
also in patients admitted to hospital without OD (Kocsis et al., 2009, Penttila 
et al., 2016).  
Phospholipase A2 (PLA2) is a lipolytic enzyme which generates 
inflammatory precursors. It is distributed widely in tissues throughout the 
body, and it is especially strongly present in pancreatic juice and tissue. It is 
synthesised in acinar cells as inactive precursors, and during AP, it is released 
into the circulation. PLA2 has been studied as a marker for AP, and it 
correlates with the severity of AP (Gronroos et al., 1992, Nevalainen et al., 
1993). The PLA2 activity profile resembles that of CRP (Puolakkainen et al., 
1987), and in SAP, PLA2 correlates with the presence of SIRS (Hietaranta et 
al., 1999). However, PLA2 assessment has technical limitations with high costs 
and a cumbersome technique, and it has not been used in the diagnosis of AP 
(Lippi et al., 2012a). 
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2.2.4 TREATMENT OF AP 
 
There is no curative therapy for AP. Early therapy consists of supportive 
treatment, including adequate fluid resuscitation and pain management. In 
the later course of the disease, interventions may be need.  
Guidelines recommend early fluid resuscitation in the emergency room to 
reduce morbidity and mortality (Tenner et al., 2013). However, aggressive 
fluid therapy may lead to respiratory complications and abdominal 
compartment syndrome (Mao et al., 2010).  
A secondary infection of pancreatic or peripancreatic necrosis is thought to be 
the result of bacterial translocation from the gut (Wittau et al., 2011). 
Antibiotics are indicated only if infections are diagnosed with bacterial 
cultures (Gaieski et al., 2010, Vege et al., 2018). 
Early oral feeding within 24 hours of onset is recommended (Lankisch et al., 
2015). Enteral nutrition maintains the mucosal barrier of the gut and 
decreases bacterial translocation, reducing infection of pancreatic necrosis 
and other AP complications, as well as the need for interventions for necrosis 
and MODS (Vege et al., 2018, Windsor et al., 1998).   
A necrotic infected collection unresponsive to conservative treatment is an 
indication for intervention. A step-up approach with catheter drainage is 
considered standard care. It is followed by a minimally invasive necrosectomy 
or an open necrosectomy in rare cases (Working Group IAP/APA Acute 
Pancreatitis Guidelines, 2013, Tenner et al., 2013).  
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3 PRESENT INVESTIGATION 
3.1 AIMS OF THE STUDY 
The goal of this study was to investigate ERC in BDI treatment, the prevention 
of PEP and the diagnosis of PEP and AP. The specific aims were as follows: 
 
I. To explore whether ES or ES and stenting is superior in Amsterdam 
A class BDIs. 
 
II. To evaluate if rectal diclofenac has a prophylactic effect in PEP in an 
endoscopic unit with a low PEP rate. 
 
III.  To explore the urine T-2 dipstick test in the early diagnosis of PEP. 
 
IV. To explore whether serum SPINK1, T-1, T-2, T-3, and trypsin-2-AAT 
can predict SAP. 
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3.2 MATERIALS AND METHODS 
This study was designed and carried out in HUH between 2014 and 2018. All 
the patients in the study were referred to the abdominal centre between 2004 
and 2018. The HUH Ethics Committee approved all the study protocols. 
3.2.1 PATIENTS  
 
Studies I and II are retrospective studies, studies III and IV are prospective 
studies. Patients in studies I-III are patients referred to the HUH Endoscopic 
Unit for ERCP; patients in study IV are patients referred to the HUH 
emergency room due to AP. 
 STUDY I 
 
This study of the treatment of BDI was designed as a retrospective study which 
included 99 patients referred to the Helsinki University Hospital Endoscopic 
Unit between 2004 and 2014 due to a suspected BDI after cholecystectomy. 
All the patients included in the study demonstrated a bile leak or biliary duct 
stricture on ERC. The patients’ clinical course and the outcome of the 
treatment were retrieved retrospectively from patient files, and all ERC images 
were reviewed. 
Patients with an Amsterdam type A bile leak were grouped into the ES 
group if the treatment modality was ES alone, and into the ES with stenting 
group (EST group) if the treatment modality was ES and stenting. Since the 
study was retrospective, the treatment modality was chosen by the endoscopist 
based on personal experience and published information. We compared these 
groups to clarify whether stenting is superior to ES alone in the treatment of 
Amsterdam type A bile leaks. The inclusion criteria for the whole cohort was 
visible BDI in a cholangiogram, and for the ES and EST subgroup, analysis 
demonstrated Amsterdam type A BDI. Patient characteristics are shown in 
Table 7. 
 STUDY II 
 
This study, evaluating the preventive effects of diclofenac in PEP, was designed 
as a retrospective observational cohort study of 2,000 ERCP patients referred 
to the Helsinki University Hospital Endoscopic Unit before and after 2013, 
when routine diclofenac administration for ERCP patients began. 1,000 
patients after November 2013 received 100 mg diclofenac rectally before ERCP 
(diclofenac group [DG]), and 1,000 patients treated without diclofenac before 
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November 2013 served as a control group (control group [CG]). We compared 
these groups and clarified whether there were differences between the groups 
or subgroups in the incidence of PEP. We reviewed patients’ records for the 
required information. The inclusion criterion was age ≥18. The Exclusion 
criteria were renal insufficiency, NSAID allergy, elevated plasma amylase, and 
AP diagnosis prior to ERCP. Patient characteristics are shown in Table 8. 
 STUDY III 
 
This prospective study of a urine T-2 dipstick test in PEP diagnosis consisted 
of 400 ERC patients referred to the Helsinki University Hospital Endoscopic 
Unit between 2011 and 2018. Inclusion criteria were age ≥18, native papillae, 
and no history of chronic or acute pancreatitis prior to ERC. Patient 
characteristics are shown in Table 9. 
 STUDY IV 
 
This prospective study of prognostic biomarkers in severe AP consisted of 239 
patients referred to the Helsinki University Hospital emergency room due to 
AP between 2005 and 2012. All the included patients had a diagnosis of AP 
with an onset of the disease less than 72 h previously. Exclusion criteria for 
this study were an age of less than 18 and chronic pancreatitis. Patients were 
classified in groups based on the severity of AP according to revised Atlanta 
criteria: mild, moderately severe, and severe. Patient characteristics are shown 
in Table 10. 
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Table 7 Study I: Patient characteristics (n=99) 
Age, years* 60 (27-93) 
Female gender 54 (55) 
Type of cholecystectomy 
    Laparoscopy 58 (59) 
   Laparotomy 13 (13) 
   Conversion from laparoscopy to laparotomy 28 (28) 
   Elective operation 52 (53) 
   Acute cholecystitis 45 (45) 
Reported surgical problems  
   Acute cholecystitis 32 (32) 
   Chronic cholecystitis 17 (17) 
   Bleeding 5 (5) 
   Stone in cystic duct 3 (3) 
   Wide cystic duct 3 (3) 
   Abscess 2 (2) 
Injuries detected intraoperatively  
   Bile leak 3 (3) 
   Common bile duct injury 5 (5) 
   Complete transection of common bile duct 1 (1) 
Biloma drainage after operation  79 (80) 
Days of fistula closure * 4 (0-52) 
Hospitalisation days after first ERC* 5 (0-65) 
Data are presented as *median (range) or numbers and (%). ERC = endoscopic retrograde 
cholangiography 
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Table 8 Study II: Patient and procedure characteristics and comparison between 
control group (CG) and diclofenac group (DG) (n=2000) 
 CG (n = 1,000) DG (n = 1,000) P 
Age, (years)* 63 (18-100) 64 (18-97) 0.358 
Female 421 (42) 430 (43) 0.684 
ASA grade 
  1 31 (3) 39 (4)  
  2 244 (24) 215 (22)  
  3 536 (54) 589 (59)  
  4 189 (19) 157 (16) 0.697 
BMI (kg/m2) * 24.8 (13-56) 24.8 (12-56) 0.897 
Native papilla  535 (54) 523 (52) 0.624 
History of AP 137 (14) 142 (14) 0.747 
History of PEP 16 (2) 6 (1) 0.032 
Biliary stone 286 (29) 293 (29) 0.762 
Biliary stricture 399 (40) 412 (41) 0.566 
PSC 4 (0) 8 (1) 0.247 
Bile duct injury 38 (4) 20 (2) 0.016 
Liver transplantation 36 (4) 14 (1) 0.002 
Pseudocysts 99 (10) 84 (8) 0.239 
Chronic pancreatitis 216 (22) 209 (21) 0.702 
Biliary stent 386 (39) 381 (38) 0.483 
Biliary sphincterotomy 500 (50) 468 (47) 0.133 
Biliary stone removal 218 (22) 240 (24) 0.124 
Pre-cut 15 (2) 18 (2) 0.593 
Pancreatic sphincterotomy 192 (19) 158 (16) 0.045 
Pancreatic stent 239 (24) 258 (26) 0.313 
Pancreatic brush cytology 32 (3) 41 (4) 0.340 
Pseudocyst drainage 18 (2) 17 (2) 0.860 
Papillectomy 12 (1) 12 (1) 1.000 
Native papilla    
    Difficult biliary cannulation  168 (17) 160 (16) 0.629 
    Cannulation time (s) 105 (0-3720) 91 (0-3030) 0.421 
Pancreatic opacification  332 (33) 347 (35) 0.479 
Duration of ERCP (min) * 21 (3-153) 21 (2-148) 0.005 
Hospital days after ERCP* 1 (0-106) 1 (0-87) 0.015 
 
Data are presented as *median (range) or numbers and (%). ASA = American Society of 
Anesthesiology; BMI = body mass index; ² ERCP grade according to Cotton classification (Cotton et 
al., 2011); PSC = primary sclerosing cholangitis. 
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Table 9 Study III: Patient Characteristics (n=400) 
Age, years* 71 (18 - 100) 
Female gender 228 (56.9) 
ERCP Indications:  
   Biliary duct stones 275 (69) 
   Malignant biliary stricture 118 (30) 
   Sphincter of Oddi dysfunction 1 (0.3) 
   Leak after cholecystectomy 2(0.5) 
   Other 4 (1) 
Comorbidities:  
   Diabetes 77 (19) 
   Cardiovascular disease 251 (63) 
   Pulmonary disease  43 (11) 
   Elevated pre-ERCP p-bilirubin  302 (76) 
   Post- ERCP hyperamylasemia ≥ 3 x URL 50 (13) 
Data presented as *median (range) or number of patients (%). URL upper reference limit 
 
 
Table 10          Study IV: Patient Characteristics (n=239) 
 
Age, years* 49 (19-86) 49 (19-91) 48 (29-81) 
Aetiology of AP    
   Alcohol 126 (73) 25 (65) 25 (86) 
   Biliary 28 (16) 10 (26) 2 (7) 
   Idiopathic or other 18 (10) 3 (8) 2 (7) 
Onset of symptoms (h)* 24 (2-72) 24 (4-72) 24 (2-72) 
CRP (mg/L)* 22 (3-369) 20 (3-383) 27 (3-414) 
Creatinine (μmol/L)* 65 (40-207) 71 (46-313) 85 (48-1,066) 
SOFA* 0 (0-9) 0 (0-8) 4 (0-15) 
APACHE II* 5 (0-13) 6 (0-14) 7 (0-21) 
MMS * 0 (0-3) 0 (0-3) 0 (0-5) 
MMS < 2  172(100) 33 (87) 21 (72) 
MMS ≥ 2 o 0 (0) 5 (13) 8 (28) 
Renal replacement therapy 0 (0) 0 (0) 15 (52) 
Mechanical invasive ventilation  1 (0.6) 4 (11) 25 (86) 
Hospital days* 4 (0-98) 11 (3-20) 27 (1-108) 
Mortality  1 (0.6) 1 (3) 6 (22) 
Data are presented as *median (range) or number and (%). APACHE II was determined within 24 h of 
admission using the most abnormal value for each physiological variable. APACHE acute physiology 
and chronic health evaluation, CRP C-reactive protein, MMS modified Marshall score, SOFA sepsis-
related organ-failure assessment score. 
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3.2.2 CLASSIFICATIONS AND DEFINITIONS 
 
BDI classification and grade 
  
BDIs type were classified according to the Amsterdam criteria (Bergman et al., 
1996). Severity of bile leak was graded from endoscopic images as LG if the 
leak was visible after intrahepatic opacification from the distal part of the 
common bile duct and HG if the leak became visible in cholangiography before 
intrahepatic opacification (Dolay et al., 2010).  
 
BDI healing 
 
Healing of the bile duct leak was diagnosed when a patient was symptomless 
without visible bile in the drains, and no adverse events appeared. Bile duct 
strictures were diagnosed as healed when there was no visible stricture present 
in the control ERC when the stents were removed.  
 
PEP 
 
The criteria used for PEP diagnostics were a new onset of typical epigastric 
abdominal pain after ERCP lasting at least 24 h, with elevated plasma 
pancreas-specific amylase or amylase levels more than 3 times the upper 
reference limit and/or typical diagnostic findings in CT or MRI (Cotton et al., 
2009). PEP was further graded as mild, moderately severe, or severe AP 
according to the Revised Atlanta Classification (Sarr et al., 2013), and as mild, 
moderate, or severe according to Cotton’s Classification (Cotton et al., 2009). 
 
AP 
 
AP diagnostic criteria were persistent typical epigastric abdominal pain with 
elevated plasma pancreas-specific amylase or amylase at least three times the 
upper reference limit and/or typical diagnostic findings of AP in CT or MRI. 
AP was graded according to the Revised Atlanta Classification as mild (without 
OD or systemic complications), moderately severe (with transient OD that 
resolves within 48 h, and/or local/systemic complications), or severe (with 
persistent OD lasting more than 48 h) (Sarr et al., 2013). At the time of 
admission to hospital, the presence of OD was assessed according to Modified 
Marshall Score. The score of three organ groups (respiratory, renal, and 
cardiovascular) is evaluated, and each of these organ groups can receive a 
score of 0 - 2, depending on the level of organ function. A total calculated sum 
of scores ? 2 indicates OD (Marshall et al., 1995). OD is determined as 
transient if it resolves within 48 h, and as persistent if it persists over 48 h. 
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3.2.3 SAMPLING AND ANALYTICAL METHODS 
 
In study II, plasma pancreas-specific amylase or amylase levels were 
analysed before and 4 h after ERCP to identify the possible development of 
PEP. If patients remained in hospital overnight, plasma pancreas-specific 
amylase was also measured 24 h after ERCP. 
In study III, we analysed plasma or pancreas-specific amylase, bilirubin, 
urine T-2 and urine T-2 with a dipstick in all patients before ERCP and 4 h 
after ERCP. If a patient stayed overnight, 24 h tests were also taken. Pancreas-
specific amylase and plasma amylase were measured according to hospital 
routine with an Abbott Architect analyser. Urine T-2 was measured by a 
quantitative time-resolved immunofluorometric assay (IFMA). A urine T-2 
dipstick test (Actim Pancreatitis; Medix Biochemica, Kauniainen, Finland) 
was dipped into the fresh urine sample, and the result was detectable within 5 
minutes. The dipstick test has a detection line and reference line, which both 
turn to blue if the urine T-2 concentration exceeds 50 ?g/l, indicating a 
positive dipstick test. 
In study IV, we measured serum SPINK1, T 1-3, trypsin-2-AAT, plasma 
pancreas-specific amylase or amylase, creatinine, and CRP o-12 h after 
admission to hospital in all AP patients. Serum was separated and stored until 
analysed at -20 ?C. SPINK1, T 1-3, and trypsin-2-AAT were quantified by 
monoclonal antibodies-based time-resolved immunofluorometric assays. 
Plasma pancreas-specific amylase or amylase, creatinine and CRP 
concentrations were analysed as hospital routine blood samples with a 
Modular P clinical chemistry analyser (Hitachi, Tokyo, Japan) using a 
Pancreatic-Amylase liquid kit, an Alpha-Amylase liquid kit, a CREA plus kit 
and a Tina-quant CRPL3 kit respectively. 
3.2.4 STATISTICAL ANALYSIS 
 
Statistical analyses were performed on SPSS version 22.0 (SPSS, IBM 
Corporation, Somers, NY, USA) statistical software and in study III also 
Analyse-it software for Microsoft Excel 2016 (version 4) was used. The data is 
presented as median and range, or number and percentage. Comparisons were 
made between groups by Chi-square or Fisher’s exact tests for categorical 
variables, and continuous or ordinal variables were compared by the 
Wilcoxon-Mann-Whitney U test or the Kruskal-Wallis test. Comparisons 
between three ordered groups were made using the Jonckheere-Terpstra trend 
test. Subgroup-analyses were performed using logistic regression analysis. To 
identify potential confounding variables, all the subgroups with P <0.05 in the 
univariate analysis were selected for a multivariate logistic regression analysis. 
The agreement between the quantitative urine T-2 test and the dipstick test 
was evaluated in study III with kappa statistics (? < 0.20 indicates poor 
agreement, and ? > 0.81 very good agreement) (Landis et al., 1977). 
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To clarify the predictive value of a biomarker in study IV, a receiver operator 
characteristic (ROC) curve analysis was performed, and the area under the 
curve (AUC) was calculated. AUC 1.0 is the best result for a test, indicating 
100% specificity and sensitivity, and 0.5 indicates no discriminatory power. 
Optimal cut-off value was determined from the ROC curve to obtain 93% 
specificity and the corresponding sensitivity for each biomarker. The positive 
and negative likelihood ratio and diagnostic odds ratio with 95% confidence 
intervals were calculated for these cut-off values (Glas et al., 2003, Newcombe, 
1998).  
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3.3 RESULTS 
3.3.1 STUDY I: ERCP IN MANAGEMENT OF BDI 
 
The majority of the total of 99 patients had Amsterdam type A BDIs (74 
patients, 75%), and the leak was most frequently found in the cystic duct (60 
patients, 64%). The type and treatment of the BDI are presented in Table 11. 
 
 
Table 11  Characteristics of BDI and treatment 
                                                                                                            Number of patients (%) 
Type of BDI (Amsterdam classification)                  
     A 74 (75) 
     B 17 (17) 
     C 4 (4) 
     D 4 (4) 
Bile duct leak 94 (95) 
Location of leak  
     Cystic duct 60 (64) 
     Duct of Luschka or peripheral radicals 21 (22) 
     Common bile duct 13 (14) 
Grade of the leak 
     HG 43 (46) 
     LG 51 (54) 
Common bile duct stones 17 (17) 
Bile duct stricture 12 (12) 
Location of stricture  
     Common bile duct 8 (67) 
     Common hepatic duct 2 (17) 
     Right hepatic duct 2 (17) 
Endoscopic management 
     Sphincterotomy  56 (57) 
     Sphincterotomy and biliary stent  37 (37) 
     Biliary stent without sphincterotomy 1 (1) 
BDI= bile duct injury; HG = high-grade; LG = low-grade 
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Management of Amsterdam type A BDIs 
 
All 74 patients with Amsterdam type A BDI were treated successfully in ERC. 
Of these patients, we further explored a group of 71 patients with native 
papillae who were treated with ES alone (ES group, 50 patients) or with ES 
with stenting (EST group, 21 patients). We compared the success of primary 
treatment between these groups and found no difference in the outcomes (P= 
0.951). The results did not differ in the closure time of the leak (P = 0.179), 
discharge time from the hospital (p = 0.298) or in primary healing rate in LG 
leaks (P = 1,000) and HG leaks (p = 1,000) (Table 12). However, more ERCs 
per patient were needed in the EST group than in the ES group as the stents 
needed to be removed in an additional ERC (2.1 [mean] vs 1.2, respectively, P 
= 1.000). Five patients (10%) in the ES group needed additional ERCs and 
stenting before healing. Two patients (10%) in EST group needed secondary 
stenting before the leak closed. We found no difference in the efficiency of 
these two treatment modalities.  
 
Management of Amsterdam type B, C, and, D BDIs 
 
Seventeen patients presented Amsterdam type B leak in ERC. The leak 
originated from the common bile duct in four patients, the main hepatic duct 
in five patients, and the right hepatic duct in one patient. Stricture with a 
concomitant cystic stump leak was present in 7 patients. Endoscopic treatment 
with stenting was successful in 14 out of 17 patients in this group. Three 
patients needed operative treatment.  
All four patients with Amsterdam type C injuries (strictures) were 
successfully treated with multiple plastic or covered self-expandable metallic 
stents in ERC. No operative treatment was needed for this group. 
All ERCs in patients diagnosed with an Amsterdam type D injury remained 
diagnostic. They all underwent surgery and a Roux-en-Y hepaticojejunostomy.  
 
Outcome of the treatment 
 
Endoscopic treatment succeeded in 93% of all BDI patients. Two patients (2%) 
had PEP (mild and moderately severe according to the Atlanta classification). 
There were no cases of bleeding, perforation, cholangitis, or mortality related 
to ERC. Patients undergoing surgery had no long-term complications. 
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Table 12 Comparison of therapy of Amsterdam A BDI treatment between the 
endoscopic sphincterotomy (ES group) and endoscopic sphincterotomy and 
stenting group (EST group) 
 ES group n = 50 EST group n = 21 
 
P  
Patient and injury characteristics 
 
Female 27 (54) 12 (57) 0.808 a 
Age (years)* 57 (27-88) 66 (32-93) 0.053 b 
Type of leak 
   Cystic stump 32 (64) 16 (76) 0.316 a 
   Duct of Luschka 18 (36) 5 (24) 0.316 a 
   LG/ HG leak 35/15 (69/31) 12/9 (57/43) 0.296 a 
Endoscopic treatment and outcome 
   1.ERC success 45 (90) 19 (90) 0.951 a 
   2.ERC  5 plastic stents 19 stent removal 
1 stone removal          
and stenting 
1 stent change 
 
   3.ERC  5 stent removal 
1 nasobiliary stent 
1 stent removal 
1 diagnostic 
1 additional stent  
 
   4. ERC  1 stent removal  
Total number of ERCs 60 46 0.000 c 
Drainage days after ERC * 4 (0-21) 3 (1-14) 0.179 c 
Hospitalisation days after 
ERC * 
4 (1-53) 4 (1-65) 0.298 c 
Stent days * 40 (31-63) 54(29-297) 0.338 c 
Follow-up time, months* 51 (1-129) 28(1-116) 0.028 c 
Post ERCP pancreatitis 2 (4) 0 (0) 0.353 a 
Data are presented as *median (range) or numbers and (%). BDI biliary duct injury; a Chi-
square test; b Unpaired independent t-test; c Wilcoxon- Mann- Whitney test, LG low-grade 
leak, HG high-grade leak 
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3.3.2 STUDY II: DICLOPHENAC IN PREVENTION OF PEP 
 
In this study, 97% of the 2,000 ERCP cases were therapeutic, and the most 
frequent procedures were biliary ES (in 1,327 patients [66%]), biliary stent 
placement (in 749 patients [37%]) and biliary stone extraction (in 459 patients 
[23%]). Slightly more than half the patients had native papillae (1,058 
patients, [53%]) and cannulation was ranked as difficult on 328 occasions 
(31%). The median cannulation time in native papillae cases was 92 s, and the 
median total time of the procedure was 21 minutes in all patients as well as in 
native papilla cases. Two study groups, DG and CG, did not differ in their 
patient characteristics or the incidence of PEP, which was 2.8% in both the 
groups and also in the entire cohort. Furthermore, there was no difference 
between the groups in the severity of PEP.  
We found no subgroup that would have benefitted from rectal diclofenac 
(Table 13). In univariate analysis, the risk factors for PEP were native papilla, 
pancreatic ES, pancreatic brush cytology, papillectomy, pre-cut ES, difficult 
cannulation, and a prolonged procedure time. A pair-wise logistic regression 
of these variable with diclofenac, showed no effect of diclofenac in the 
development of PEP. In a multivariate analysis, significant factors associated 
with the risk of PEP were pancreatic ES, pancreatic brush cytology, difficult 
cannulation, and a prolonged procedure time. Diclofenac showed no effect on 
the risk of PEP (Table 14). 
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Table 13 Comparison of incidence of post ERCP pancreatitis (PEP) risk factors 
between the study groups 
Risk factors Control group 
n/N (%) 
Diclofenac group 
n/N (%) 
P 
Female gender 13/408 (3.2) 14/416 (3.4) 0.889 
Native papillae 21/535 (3.9) 19/523 (3.6) 0.803 
      Female  12/241 (4.9) 13/249 (5.2) 0.900 
      Female < 40 years              1/24 (4.2) 0/28 (0) 0.462* 
      Difficult biliary cannulation   12/156 (7.7) 10/150 (6.7) 0.747 
Previous pancreatitis 2/137 (1.5) 2/142 (1.4) 1.000* 
Previous PEP 1/16 (6.3) 0/6 (0) 1.000* 
Duration of ERCP > 40 min 12/145 (8.2) 9/169 (5.3) 0.330 
Normal serum bilirubin 14/457 (3.1) 10/485 (2.1) 0.330 
ERCP procedures 
      Pancreatic sphincterotomy 17/192 (8.9) 12/158 (7.6) 0.671 
      Biliary sphincterotomy 21/500 (4.2) 13/468 (2.8) 0230 
      Pancreatic duct dilatation 5/108 (4.6) 4/120 (3.3) 0.739* 
      Pancreatic stent placement 
      in chronic pancreatitis 
6/239 (2.5) 10/258 (3.9) 0.389 
      Pancreatic brush cytology 8/158 (5.2) 6/194 (3.1) 0.335 
      Pancreatic duct opacification 10/322 (3.1) 14/333 (4.2) 0.471 
Pre-cut 1/15 (6.7) 2/18 (11.1) 1.000* 
Papillectomy 1/12 (8.3) 3/12 (25) 0.590* 
Data are presented as numbers and (%) n number of pancreatitis cases.  N group size; *Fisher’s exact 
test; ERCP endoscopic retrograde cholangiopancreatography 
 
Table 14  Logistic regression analysis in the effect of diclofenac on the risk of 
PEP, when adjusting for the risk of PEP in a univariate analysis 
 OR           (95%CI) P 
Diclofenac administration  1.031 (0.60- 1.79) 0.913 
Pre-cut 1.125 (0.29- 4.39) 0.865 
Native papilla  1.099 (0.53- 2.28) 0.800 
Papillectomy 2.818 (0.788- 10.08) 0.111 
Difficult biliary cannulation 2.145 (1.10- 4.20) 0.026 
Pancreatic cytology 3.189 (1.233- 8.250) 0.017 
Pancreatic sphincterotomy 2.857 (1.49- 5.47) 0.002 
Duration of procedure 1.020 (1.01- 1.03) 0.001 
OR odds ratio; CI confidential interval 
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3.3.3 STUDY III: URINE T-2 DIPSTICK TEST IN PEP DIAGNOSIS 
 
Of the 400 patients in this cohort, PEP developed in 15 cases (3.8%). There 
were no severe PEPs among these patients; 14 had mild PEP, and one was 
diagnosed as moderately severe according to the Atlanta classification.  
A baseline dipstick test was taken for all 400 patients, and it was negative 
in 279 patients. The 4 h test for these was positive in 58 patients, including 6 
PEP cases.  In 214 cases with the negative 4 h dipstick test, 6 developed PEP, 
and 3 of these patients had a positive 24 h test, while 3 tests were missing. In 
all cases, the negative dipstick test excluded PEP (Table 15). 
In all patients, regardless of the baseline results, the 4 h dipstick test was 
negative for 240 of 388 patients, and the 24 h test in 154 of 269 patients. The 
4 h dipstick test was positive in 139 (35%) patients without PEP. However, 
none of the patients with both negative 4 and 24 h dipstick tests developed 
PEP.  
When the dipstick test was evaluated with persistent abdominal pain 
symptoms (diagnostic criteria for PEP), the accuracy of diagnostics improved: 
4 h after the ERCP dipstick test sensitivity was 60%, specificity 99%, the 
positive predictive value 71%, and the negative predictive value 98%. The 24 h 
dipstick test sensitivity was 100%, specificity 98%, the positive predictive value 
71% and the negative predictive value 100% (Table 16). 
We also measured urine T-2 quantitative concentrations and compared 
them with dipstick performance. The kappa value 4 h after ERCP was 0.828, 
and 24 h after ERCP it was 0.773. The concentrations of urine T-2 increased 
significantly during this time. 
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Table 15          Urine trypsinogen-2 dipstick results 
ERCP endoscopic retrograde cholangiopancreatography; False positive test = positive test without 
diagnosed PEP; False negative test = negative test in patient with diagnosed PEP 
 
 
 
 
 
Table 16      Diagnostic performance of urine trypsinogen-2 dipstick test with 
abdominal pain detecting PEP 
 Sensitivity  
(95% CI) % 
Specificity  
(95% CI) % 
PPV % NPV % 
4 h dipstick positive 60  
(35-80) 
99  
(97-99) 
64 98 
24 h dipstick positive  100 
(70-100) 
98  
(96-99) 
71 100 
PPV positive predictive value; NPV negative predictive value; CI confidential interval                          
 
 
 
 
 
 
 Positive (%) False 
positive 
(%) 
Negative (%) False 
negative 
(%) 
Missing (%) 
All patients  
Before ERCP 121 (30) 121 (30) 279 (70) 0 0 
4 h after ERCP 148 (37) 139 (35) 240 (60)  6 (1.5) 12 (3) 
24 h after ERCP 115 (29) 109 (27) 154 (39)  0 131 (33) 
PEP patients  
Before ERCP 2 (13) 2 (13) 13 (87) 0 0 
4 h after ERCP 9 (60) 0 6 (40) 6 (40) 0 
24 h after     ERCP 9 (100) 0 0 0 (0) 6 (40) 
Patients with abdominal pain after ERCP 
Before ERCP 4 (17) 4 (17) 20 (83) 0 0 
4 h after ERCP     14 (58) 5 (21) 10 (41) 6 (25) 0 
24 h after ERCP 14 (58) 5 (21) 4 (17) 0 6 (25) 
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3.3.4 STUDY IV: SPINK1, T 1 - 3, AND TRYPSIN-2-AAT IN PREDICTING 
SEVERE AP 
 
According to the Atlanta criteria, AP was diagnosed as mild in 172 (72 %), 
moderately severe in 38 (16 %), and severe in 29 (12 %) cases. The great 
majority of patients (n = 226, 94%) presented without OD on admission to 
hospital. Thirteen patients (5.4 %) had OD upon arrival, and they were 
diagnosed further as transient OD in 5 patients, and persistent OD in 8 
patients. The duration of symptoms did not differ between patients with or 
without OD on admission (P = 0.05). OD developed after admission in 27 
patients; in 11 patients, OD was transient, as it was resolved within 48 h, but 
in 21 patients, OD was persistent, as it lasted over 48 h.  
Eight patients (3.3%) died during hospitalization, and 6 of these had severe 
AP. Five of the deaths occurred during the first week in hospital, and the three 
others on hospital days 13, 24 and 25. Two patients with SAP died within 24 h 
of admission, and they were not treated in ICU due to their high age and severe 
comorbidities. One patient with mild AP also died 24 h after admission: he 
committed suicide on the ward. One patient with moderately severe AP died 
on day 13 on the ward, and because the relatives prohibited an autopsy, the 
cause of death remained unclear. The other 4 dead patients had SAP. 
 
Predictors of severe AP on admission  
 
Serum levels of SPINK1, T-1 and 2, trypsin-2-AAT and creatinine correlated 
on admission with the severity of AP (P < 0.05); T3, CRP and amylase levels 
did not (Table 17). In detecting severe AP, SPINK1 was most accurate, having 
the largest AUC value (0.779 [SD, 0.054]), followed by T-2 (0.772 [SD, 
0.049]), creatinine (0.719 [SD 0.054]), trypsin-2-AAT (0.690 [SD, 0.045]), T-
1 (0.656 [SD, 0.054]), T-3 (0.600 [SD, 0.059]) and CRP (0.565 [SD, 0.062]). 
With an optimal cut-off value of 196 μg/l giving high 93% specificity, 
SPINK1 had a sensitivity of 48% and a DOR 11.3, and at a cut-off of 1,512 μg/l 
T-2 had a 93% specificity, a sensitivity of 38% and a DOR of 6.5 in diagnosing 
severe AP in all patients on admission (Table 18). Male gender, creatinine, 
SPINK1, T-1, T-2 and T-3 were associated with SAP in univariate logistic 
regression analysis. However, only SPINK1 was an independent predictor for 
OD. 
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Table 17      Concentrations of biomarkers in patients with mild, moderately severe 
and severe acute pancreatitis 
Reference range Mild AP  
(n = 172) 
Moderately  
severe AP 
(n = 38) 
Severe AP 
(n = 29) 
Pª 
SPINK1 
3 - 16 μg/l* 
41 (28-70) 51 (35-179) 176 (59-325) 0.000 
Trypsinogen-1 
7.2 - 49 μg/l* 
316 (127-551) 404 (210-953) 451 (300-451) 0.001 
Trypsinogen-2 
2.6 - 18 μg/l* 
254 (107-618) 582 (295-1100) 1186  
(440-1844) 
0.000 
Trypsinogen-3 
<4.4 μg/l* 
13 (5-25) 18 (3.3-38.5) 20.5 (8-52) 0.081 
Trypsin-2-AAT 
2.3 - 12 μg/l* 
93 (16-232) 198 (76-425) 258 (132-45) 0.000 
Creatinine 
50 - 100 μmol/l* 
65 (56-78) 72 (57-72) 84.5 (65-162) 0.000 
CRP  
< 10 mg/l* 
22 (5-92) 24 (6-24) 27 (10-27) 0.263 
Pancreatic amylase  
10 - 65 U/l* 
360 (181-1026) 657 (315-1629) 463 (203-785) 
 
0.070 
Data presented as median (interquartile range)  
AP acute pancreatitis; CRP C-reactive protein; T-2-AAT complex between trypsin-2 and α?-antitrypsin 
*Reference values for healthy individuals for trypsinogen-1, trypsinogen-2, trypsinogen-3, SPINK1, and 
complex between trypsin-2 and α?-antitrypsin (Itkonen et al., 2012, Hedstrom et al., 1994, Oiva et al., 
2011). 
ªJonckheere-Terpstra for trend 
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Predictors of severe AP in patients without OD on admission  
 
SPINK1 was the most accurate predictor for development of severe AP after 
admission, with the largest AUC value (0.742 [SD, 0.062]) followed by T-2 
(0.726 [SD, 0.063]), trypsin-2-AAT (0.657 [SD, 0.056]), creatinine (0.656 
[SD, 0.063]), T-1 (0.652 [SD, 0.071]), T-3 (0.557 [SD, 0.069]) and CRP (0.499 
[SD, 0.075]). In finding patients developing severe AP at high 93% specificity, 
SPINK1 and T-2 had the best diagnostic accuracies; with a cut-off of 166 μg/l 
SPINK1 had a sensitivity of 48% and a DOR of 11.52; with a cut-off 1375 μg/l, 
T-2 had a sensitivity of 38% and a DOR of 7.8. (Table 18) 
SPINK1, T-1, and T-2 were significant predictive markers of SAP in 
univariate logistic regression analysis, but in multivariate logistic regression 
analysis SPINK1 was the only independent predictor of SAP. 
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Table 18           Performance of biomarkers in diagnosis of severe acute pancreatitis 
 Cut-
off 
AUC 
(95% CI) 
Sensitivity 
(95% CI), 
%  
Specificity 
(95% CI), 
% 
+LR 
(95%CI) 
-LR 
(95%CI) 
DOR 
(95% 
CI) 
All patients (n = 239) 
Trypsinogen-1, 
μg/l 
1,279 0.656 
(0.550-
0.762) 
19 
(9-38) 
93 
(87-94) 
2.6    
(1.1-6.0) 
0.9  
(0.71-
1.0) 
3.0 
(1.06-
8.26) 
Trypsinogen-2, 
μg/l 
1,512 0.772 
(0.676-
0.868) 
38  
(20-50) 
93  
(89-96) 
4.7  
(2.4-9.3) 
0.7  
(0.6-0.9) 
6.5  
(2.7-
15.9) 
Trypsinogen-3, 
μg/l 
56 0.600 
(0.485-
0.715) 
24  
(12-42) 
93  
(89-96) 
3.4  
(1.5-7.6) 
0.8  
(0.7-1.0) 
4.1  
(1.5-
11.2) 
SPINK1, μg/l 196 
 
 
0.779 
(0.683-
0.876) 
48  
(31-66) 
 
93  
(87-95) 
6.3  
(3.5-11.6) 
0.6  
(0.4-0.8) 
11.3  
(4.7-
27.5) 
Trypsin-2-AAT, 
μg/l 
785 0.690 
(0.601-
0.778) 
17  
(8-35) 
93  
(89-96) 
2.4  
(0.95-
6.15) 
0.89 
(0.75-
1.06) 
2.7  
(0.9-
8.1) 
Creatinine, 
μmol/l 
111 0.719 
(0.614-
0.825) 
33  
(20-52) 
93  
(88-95) 
4.53  
(2.27-
9.00) 
0.70 
(0.54-
0.93) 
6.4 (2.5-
16.0) 
Patients presenting without OD on admission (n = 226) 
Trypsinogen-1, 
μg/l 
1,278 0.652 
(0.513-
0.790) 
22  
(11-45) 
93  
(88-95) 
3.05  
‘(1.24-
7.49) 
0.83 
(0.65-
1.05) 
3.69 
(1.20-
11.39) 
Trypsinogen-2, 
μg/l 
1,375 0.726 
(0.602-
0.850) 
38  
(21-59) 
93  
(88-96) 
5.20  
(2.51-
10.82) 
0.67 
(0.48-
0.94) 
7.80 
(2.80-
21.74) 
Trypsinogen-3, 
μg/l 
55 0.557 
(0.422-
0.691) 
21  
(11-43) 
93  
(88-95) 
3.25  
(1.13-
8.06) 
0.82 
(0.65-
1.05) 
3.96 
(1.27-
12.30) 
SPINK1, μg/l 166 0.742 
(0.620-
0.864) 
48  
(28-68) 
93  
(88-96) 
6.50  
(3.36-
12.62) 
0.57 
(0.38-
0.85) 
11.52 
(4.22-
31.45) 
Trypsin-2-AAT, 
μg/l 
785 0.657 
(0.548-
0.767) 
19  
(8-40) 
93  
(88-96) 
2.60  
(0.95-
7.13) 
0.87 
(0.71-
1.08) 
2.99 
(0.89-
9.99) 
Creatinine, 
μmol/l 
103 0.656 
(0.531-
0.780) 
19  
(8-40) 
93  
(89-96) 
3.00  
(1.08-
8.39) 
0.86 
(0.7-
1.07) 
3.48 
(1.02-
11.84) 
AUC area under the curve; DOR diagnostic odds ratio; LR likelihood ratio; OD organ dysfunction; 
Trypsin-2-AAT complex between trypsin-2 and α?-antitrypsin. 
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3.4 DISCUSSION 
3.4.1 ERCP IN TREATMENT OF BDI 
 
ERCP has become the main treatment of choice in BDIs in recent decades as 
equipment, and especially stents, have improved. However, treatment of BDI 
is a rather rare event in endoscopic units, and there is lack of large prospective 
studies of this subject. The majority of studies have explored the most usual 
type of BDI, the Amsterdam type A leak. The guidelines for treatment of BDI 
strictures originates mostly from series exploring other benign types of biliary 
stricture as well as the recommendations on the treatment of major leaks of 
the common bile duct are mainly based on studies of leaks after liver surgery. 
In this cohort of 99 patient, we had mostly Amsterdam class A injuries, and 
the number of other injury types remained too small for more than an 
observational report of cases. 
The ESGE guideline recommends endoscopic placement of plastic stents in 
the management of bile duct leaks minor to total transection of common bile 
duct or common hepatic duct (J. M. Dumonceau et al., 2018). This 
recommendation is based on three RCTs of 27, 52, and 63 patients, which 
showed that endoscopic stenting is superior to single ES, that endoscopic 
stenting with or without ES are equally efficient treatments and that the size 
of the stents (7 or 10 Fr plastic stents) has no effect on the final outcome (Dolay 
et al., 2010, Mavrogiannis et al., 2006, Katsinelos et al., 2008). In the event of 
a refractory bile leak, ESGE recommends SEMS, because a comparative study 
of 40 patients has shown FC-SEMSs to be superior to multiple plastic stents 
(Canena et al., 2015).  
Our present study’s most important finding was that ES alone and ES with 
stenting had equal 90% success in biliary leak closure, which differs from the 
ESGE guideline’s recommendations and most previous studies. The RCT, 
which is the cornerstone of the ESGE recommendation, showing the 
superiority of biliary stenting in the treatment of biliary leaks, included only 
27 patients. However, our observational retrospective study consisted of 71 
patients with dominant ES group of 50 patients. In addition to our study, two 
other studies of 31 and 207 patients demonstrate the effectiveness of biliary 
ES in the treatment of Amsterdam type A LG leaks (Aksoz et al., 2009, Sandha 
et al., 2004). We found no difference in the treatment of Amsterdam type A 
low-grade or high-grade patients. The reason to our success may be explained 
by the ES technique: in our clinic, we perform ES by cutting the sphincter 
completely, extending the incision to the maximum safe limit. Proper ES 
balances the pressure gradient between the bile duct and bowel, and enables 
free bile flow to the bowel, ending the leak. A smaller ES does not sufficiently 
balance the pressure gradient, a technical detail which may explain the 
difference between our and previous published results. There was need for 
additional stenting in 10% of both study groups. In the ES group, the failure 
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may be explained by insufficient ES: in the EST group, the plastic stent 
position may have been suboptimal, failing to balance the pressure gradient. 
Although the ES and EST groups have similar success rates, ES is a cost-
effective procedure because it does not require an additional endoscopy and 
stent removals: in the ES group, the mean number of procedures was 1.2; in 
the EST group, it was 2.2.  
3.4.2 PREVENTION OF PEP 
 
The European and Japanese societies of Gastroenterology recommend routine 
use of diclofenac for all ERCP patients without contraindications (J. 
Dumonceau et al., 2014, Mine et al., 2017). These guidelines are based on 
several meta-analyses between 2009 and 2014 dealing with RCTs showing a 
mostly positive effect on diclofenac and indomethacin in reducing PEP. The 
number of patients in these RCTs varies from 100 to 602 (Khoshbaten et al., 
2008, Elmunzer et al., 2012), and the number of patients in meta-analyses 
varies between 912 and 2,269 (Elmunzer et al., 2008, Ding et al., 2012). The 
majority of these studies have included only patients with high PEP risk, and 
thereafter the incidence of PEP in these studies has reached 26% (Khoshbaten 
et al., 2008). However, three recent RCTs (two studies of indomethacin and 
one study of diclofenac) reported controversial results, showing no role of 
rectal NSAIDs in preventing PEP in consecutive ERCP patients. They did 
show, however, the effect of NSAIDs in high-risk patients. These studies 
included 144, 449, and 665 patients, and the incidences of PEP in these studies 
were 7.6%, 6.0 %, and 6.3% respectively (Lua, Muthukaruppan & Menon, 
2015, Levenick et al., 2016, Dobronte et al., 2014). Based on these findings, the 
American Endoscopic Society recommends NSAIDs only for average and high 
PEP risk patients, not for consecutive patients as European and Japanese 
guidelines do (ASGE Standards of Practice Committee et al., 2017, J. 
Dumonceau et al., 2014, Mine et al., 2017). 
Indomethacin has been shown to be a more effective PLA2 inhibitor than 
diclofenac, and theoretically it may be superior in PEP prevention (Makela et 
al., 1997). However, there is lack of studies comparing the effects of diclofenac 
and indomethacin in preventing PEP (Lyu et al., 2018).  
Our results with a low PEP risk of 2.8% in both the study arms differ from 
majority of previous published results. We researched consecutive patients in 
a high-volume centre, including the feasible number of high-risk patients as 
well. We found no preventive or attenuating effect of diclofenac on PEP in low-
risk patients or in different high-risk subgroups. Similarly, three RCTs (Lua et 
al. 2015, Levenick et al. 2016, Dobronte et al. 2014) found no effect on 
diclofenac in preventing PEP in low-risk patients. However, our study differs 
from these in their retrospective nature, the lower rate of PEP and a larger 
number of patients. These results indicate that the role of NSAIDs in 
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preventing PEP remains unclear, and further large scale RTCs are needed to 
explore the use of NSAIDs for all patients.  
3.4.3 DIAGNOSIS OF AP 
 
Large proportions of trypsinogens are released to the systemic circulation and 
urine in the early phase of AP. Serum and urine concentrations increase within 
a few hours after the onset of the disease. This enables the use of trypsinogens, 
SPINK1 and trypsin-2-AAT in diagnosis and in the severity assessment of AP 
(Lippi, Valentino & Cervellin, 2012b). 
 
Urine T-2 dipstick in diagnosis of PEP 
 
Urine T-2 has been shown to be as effective in the diagnosis of AP as a serum 
amylase and lipase test (Rompianesi et al., 2017). Only four studies have 
evaluated the use of T-2 in the diagnosis of PEP, and three of these involved a 
dipstick test. The size and number of PEP cases in these previous studies was 
smaller than ours; there were 11 PEP cases of a total of 106 patients in the study 
of Kemppainen et al. (E. Kemppainen et al., 1997), 4 PEP cases of 29 patients 
in the study of Sankaralingam et al. (Sankaralingam et al., 2007), and 13 PEP 
cases of 150 patients in the study of Tseng et al. (Tseng et al., 2011). In the 
studies of Sankaralingam and Tseng, all patients with a positive base-line 
dipstick test were excluded. Kemppainen et al. did not test the pre-ERCP 
dipstick test; instead, they measured urine T-2 concentrations before ERCP 
and excluded all patients with high trypsinogen levels.  In our study, we had a 
surprisingly high proportion (33%) of positive pre-ERCP dipstick tests. Many 
conditions and common indications for ERCP, such as biliary tract 
malignancies, biliary stones, and biliary and hepatic inflammations, increase 
T-2 in urine (Itkonen, 2010, Hedstrom et al., 1996). However, we reasoned 
that in clinical practice, pre-ERCP dipstick tests are not taken, and we 
therefore included all patients in our analysis, regardless of the baseline 
dipstick result.  
In our entire cohort, we found the dipstick test less accurate than previous 
studies in the diagnosis of PEP. However, our result was similar to others when 
we also only analysed patients with a negative pre-ERCP dipstick test. Since 
abdominal pain is an important diagnostic criterion of PEP and needs to be 
evaluated in PEP diagnostics when amylase is used as a diagnostic test, we also 
evaluated dipstick test results with abdominal symptoms. This increased the 
accuracy of the dipstick test by up to 100% for sensitivity and 98% for 
specificity. Although the urine dipstick test indicates positive dipstick results 
in many non-PEP cases, in this study, we found that a negative test rules out, 
and a positive test with abdominal pain symptoms detects, PEP with a high 
degree of accuracy. 
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Serum levels of SPINK1, T 1 - 3, and trypsin-2-AAT in prediction of 
SAP 
 
Our major finding in this study was that SPINK1 identified nearly half the 
patients who presented without OD on admission but developed SAP later. 
Recognition of these patients is important because in SAP, two out of three 
patients develop OD early during the course of the illness, and up to 50% of 
deaths occur within the first two weeks (Padhan et al., 2018). Since a specific 
pharmacological treatment is lacking and the best results are achieved in early 
intensive care, these patients need to be recognised in the disease’s early stage. 
This diagnostic challenge has been studied since the Ranson score was 
developed in 1974, but all scores and biomarkers to date have limitations in 
their use. In recent years, there have been attempts to find a single ideal 
biochemical parameter which could precisely predict the severity of AP in the 
early course of the disease.  
SPINK1, T 1-3 and trypsin-2-AAT have previously been studied in the 
diagnosis of AP and as predictors of OD (Sainio et al., 1996b, Hedstrom et al., 
1996, Lempinen et al., 2003, Ogawa, 1988b, Oiva et al., 2011). We made 
similar observations to these earlier studies: concentrations of SPINK1, T 1-3, 
and trypsin-2-AAT increases in AP patients; SPINK1, T-1 and 2 and trypsin-2-
AAT concentrations increase with AP severity. They are, thus useful in the 
diagnosis of AP. However, our study differs from these earlier studies because 
we used the revised Atlanta classification, our cohort size was bigger and we 
analysed patients who presented without OD. A similar protocol has been used 
in studies evaluating the utility of assays of cytokines, nucleosomes and soluble 
CD73 for the development of severe AP in patients presenting without OD 
(Nieminen et al., 2014, Maksimow et al., 2014, Penttila et al., 2016). These 
markers provide sensitivities varying between 26–36% in high specificities of 
93-96%, which is very comparable with our results for T-2 (38% sensitivity 
and 93% specificity) and SPINK1 (48% sensitivity and 93 % specificity).  
Of the markers studied here, T-2 and SPINK1 are of especially great interest 
for their potential use in the diagnosis of AP and predicting the development 
of OD. SPINK1 is already available in our laboratory repertoire as a tumour 
marker (TATI). It may therefore at least have the potential to be used in 
emergency rooms in the differentiation of patients prone to developing SAP. 
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3.4.4 FUTURE ASPECTS 
 
We have questioned the guidelines for treatment of BDI Amsterdam type A 
leaks and the prevention of PEP with rectal diclofenac in our retrospective and 
relatively sizable studies.  
The Amsterdam type A leak, as one of the most frequently seen 
complications of cholecystectomy, requires a straightforward and cost-
effective method of treatment. Our result for Amsterdam type A leak treatment 
shows that ES without stenting is as effective as ES with stenting, and the 
number of endoscopies needed for the treatment with ES alone is half those 
for stenting. A lack of larger-scale RCTs makes our study more significant, and 
we can thus recommend a consideration of ES as a first treatment method in 
Amsterdam type A BDIs. Biodegradable stents have recently been studied in 
Amsterdam type A BDI treatment, and they have shown equally good results 
to plastic stents (Siiki et al., 2018). These stents seem effective, and no 
additional endoscopy is needed because they degrade. However, the price of 
the stent makes this treatment method more expensive than a single ES. 
Further larger-scale RCTs are therefore needed to compare the effectiveness 
and costs of ES, with and without biodegradable stents. The scarce cases of 
BDIs in endoscopic units and the emergency setting around these patients 
complicates the conduct of well-organised large-scale RTCs. In the HUH 
Endoscopic Unit, of 1,500 annually performed ERCPs, only an average of 10 
BDI cases appears every year. This may explain the limited series of former 
RCTs. Multi-centre studies may be an answer to this problem.  
PEP in its worse outcome is a devastating complication after ERCP. The 
discovery of a perfect preventive medication for PEP should still be the focus 
of future studies. It seems that NSAIDs may not have the preventive power we 
had hoped, since our study, with 3 RCTs, questions the use of diclofenac in the 
prevention of PEP in low-risk patients. Further randomised trials in a low-risk 
unit, as well as in low risk procedures, are needed to explore this subject. 
None of the agents studied in PEP prevention have been as promising, 
harmless and easy to use as NSAIDs. We still need to identify new agents and 
technical aspects that could be studied further in PEP prevention. Our study 
shows low PEP incidence and therefore indicates that many technical details 
may be conducted differently to prevent PEP. We use methods recommended 
in ESGE and ASGE guidelines such as guidewire-guided cannulation, the 
avoidance of the pancreatic duct opacification and early biliary pre-cut to 
prevent PEP (J. Dumonceau et al., 2014, ASGE Standards of Practice 
Committee et al., 2017). Furthermore, we use propofol-anaesthesia during all 
ERCPs, which calms the operating environment; when the patient is still and 
relaxed, all the procedure’s risks are smaller. ERCPs should also be 
concentrated in centres with feasible volumes: the more experienced 
endoscopists are, the smaller the PEP rate (Keswani et al., 2017). All these 
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technical aspects need further exploration, and they should be considered for 
adoption in clinical use in endoscopic units. 
    Although diagnosis and treatment of AP has been intensively studied 
worldwide, new and useable tools for diagnosis have not been found and the 
overall mortality of the disease has not improved significantly (Agarwal et al., 
2016). In assessing the severity of AP, CRP has remained the most frequently 
used marker, although it is far from being an optimal indicator. In our study, 
after amylase, CRP was the worst predictor of SAP, strengthening the hope of 
the development of a better clinical marker. SPINK1 is accurate in the 
diagnosis of AP, but since it detects only half the cases where OD develops, 
further improvement in its sensitivity in predicting the development of SAP is 
desirable. OD can develop after several days, and it therefore would be 
important to explore whether daily determinations of SPINK1 would improve 
the detection of OD. It is also known that serum concentrations of trypsin-2-
AAT continue to increase after the onset of the disease for at least 5 days, and 
it would also be interesting to explore its performance 48 and 72 h after 
admission. T-2 had the second-best result in our cohort in predicting OD. It is 
an interesting enzyme, because its concentration remains elevated for at least 
5 days and is higher in urine than in serum (E. A. Kemppainen et al., 1997). It 
would be interesting to use a similar study protocol to research how urine T-2 
would predict SAP. A recent Japanese study of urine T-2 concentrations 
showed that it might be a suitable marker to determine extra-pancreatic 
inflammation in AP (Yasuda et al., 2019).   
In the diagnosis of PEP, the urine T-2 dipstick test performed well 
diagnostically. It is cheap and easy to use, and could be used more widely 
clinically worldwide in endoscopic units in the diagnosis of PEP. However, 
more large-scale prospective studies are needed to explore this subject. A 
quantitative electronic dipstick reader measuring the concentrations of T-2 in 
urine could improve the dipstick test performance. It also could open new 
opportunities for further research into PEP diagnosis, as well as for the 
assessment of OD development.  
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3.4.5 STRENGTHS AND LIMITATIONS OF THE STUDY 
 
Some strengths and limitations of the study are worth mentioning. 
 Studies I and II are retrospective in their nature, which naturally affects 
their results. However, there are only a few randomised studies of the 
endoscopic treatment of BDI, and the number of patients in them is smaller. 
Our study of 71 Amsterdam type A cases is noteworthy due to the size of the 
cohort, but the study’s retrospective setting creates some limitations. Since the 
treatment modality was chosen by an endoscopist based on personal 
experience and not a randomly, there may be a bias in the study results. 
Furthermore, the exact time of fistula closure is unclear, because we did not 
follow the fistulas with serial repeat cholangiograms. Additionally, the grading 
of BDI according to Amsterdam classification and of the LG and HG leaks were 
conducted retrospectively, exploring cholangiograms and patient records.  
Our cohort in study II, exploring the effects of diclofenac in the prevention 
of PEP in 2,000 patients is much larger than any published RTC and even 
some of the meta-analysis of this subject (Yaghoobi et al., 2013, Sun et al., 
2014, Yuhara et al., 2014, Dai, Wang & Zhao, 2009). Due to the retrospective 
nature and inclusion criteria of the study, the study groups have some 
differences in their characteristics. More trainees were involved in ERCP in 
DG than CG. However, all the procedures were performed the same way and 
under the supervision of the same four experienced endoscopists who 
conducted most of the ERCPs. Trainees performed the easiest procedures, and 
their risk of PEP remained low (1.8-2.3%). Analyses of the 1,742 patients 
whose procedures were performed by the experienced endoscopists revealed 
that trainee involvement had no effect on the results: the PEP risk for all 
subgroups of patients were same in the DG and CG in whole cohort. 
Furthermore, more ES was done in the CG than in DG, and since pancreatic 
ES is a known risk factor for PEP, this also proved indirectly the diclofenac’s 
inefficiency. 
Study III, which examines the performance of the dipstick test in the 
diagnosis of PEP, is the largest to date. In addition to the study’s size, our 
strength lies in the inclusion of all positively tested pre-ERCP dipstick patients 
in the analysis. Our study is the first to explore the dipstick test in clinical use 
in an endoscopic unit and to use the newest consensus criteria for PEP. It is a 
limitation, despite the size of the study, that we did not have significantly more 
PEPs than in previous studies and no cases of severe PEP. Some dipstick tests 
were lacking, mainly because 21% of patients were discharged from the 
hospital within a few hours after ERCP. This also complicated the analyses. 
Study IV is a prospective study, and, to the best of our knowledge the largest 
of the performance of SPINK1, T-1 to 3 and trypsin-2-AAT in the diagnosis of 
SAP. It is also the first study of studied markers that has used the revised 
Atlanta criteria to distinguish between moderately severe and severe AP, and 
to explore the development of SAP in patients presenting without OD on 
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admission. A limitation of study IV is the limited number of SAP patients. 
Furthermore, the number of patients who developed SAP after admission 
might have been larger. However, our cohort of 29 SAP patients, including 21 
patients who developed SAP after admission, is larger than in studies of other 
markers predicting SAP (Maksimow et al., 2014, Nieminen et al., 2014, Pantile 
et al., 2016). 
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3.5 CONCLUSIONS 
 
I) ES is equal to ES and stenting in the treatment of Amsterdam type 
A bile duct leaks. 
 
II) Rectal diclofenac shows no effect on the prevalence of PEP in a 
centre with a low risk of PEP. 
 
III) A negative urine T-2 dipstick test rules out PEP 4 h after ERCP; a 
positive test with abdominal pain symptoms reveals PEP to high 
degree of accuracy. 
 
IV) SPINK1 is an independent predictor of SAP at the time of admission 
to the hospital. 
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